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GLOSSARY OF TERMS 
Acceptable Daily Intake (ADI) – The amount of a substance that can be 
ingested daily for an entire lifetime without causing appreciable adverse effects. 
It is expressed in mg/kg body weight/day. 
Active Pharmaceutical Ingredient (API) – Any substance intended to be used 
in the manufacture of a medicinal product and that, when so used, becomes an 
active ingredient of the medicinal product. Such substances are intended to 
furnish a pharmacological activity or other direct effect in the diagnosis, cure, 
mitigation, treatment or prevention of disease, or to affect the structure and 
function of the body. 
Adverse Drug Reaction (ADR) – Any noxious or unintended reaction to a 
drug that is administered in standard doses by the proper route for the purpose 
of prophylaxis, diagnosis, or treatment. 
Bioavailability – The rate and extent at which the API is absorbed from a phar-
maceutical dosage form and becomes available at the site(s) of action. 
Bioequivalence – Two pharmaceutical products are bioequivalent if they are 
pharmaceutically equivalent or pharmaceutical alternatives, and their bio-
availabilities, in terms of peak (Cmax and Tmax) and total exposure (area under 
the curve) after administration of the same molar dose under the same condi-
tions, are similar to such a degree that their effects can be expected to be essen-
tially the same. 
Confidence Interval (CI) – A range, calculated from sample data, within 
which a population parameter, such as the population mean, is expected to lie, 
with a given level of confidence. 
Dosage Form – A dosage form is the physical form in which a drug is produced 
and dispensed, such as a tablet, a capsule, or an injectable. 
Drug – Any substance for human or veterinary use that is intended to modify or 
explore physiological systems or pathological states for the benefit of the 
recipient. 
Drug Product – A finished dosage form, for example, tablet, capsule, or 
solution, that contains an active ingredient, generally with excipients, that has 
been prepared for consumer use and that has undergone all stages of production 
including packaging and labeling. In this thesis, the term drug product, pharma-
ceutical product, medicine, and product are used interchangeably. 
Excipient (pharmaceutical excipient) – Pharmaceutical excipients are sub-
stances that are included in a pharmaceutical dosage form not for their direct 
therapeutic action, but to aid the manufacturing process, to protect, support or 
enhance stability, or for bioavailability or patient acceptability. 
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Functionality – A desirable property of an excipient that aids and/ or improves 
the manufacture, quality, or performance of the drug product. 
Gestational age (GA) – Time from the first day of last normal menstrual period 
to date of birth, usually expressed in complete weeks. When a pregnancy has 
been achieved by assisted reproductive technology, GA is calculated from two 
weeks before the date of conception. 
Good Clinical Practice (GCP) – An international ethical and scientific quality 
standard for designing, conducting, recording and reporting trials that involve 
the participation of human subjects. 
Good Laboratory Practice (GLP) – A code of standards concerning the 
testing of medicines in laboratories during their development. 
Good Manufacturing Practice (GMP) – Minimum requirements for the 
quality management system methods, and facilities or controls to be used for the 
manufacture, processing, packing, or holding of a drug product and its 
ingredients. 
Harm – Damage to health, including the damage that can occur from loss of 
product quality or availability. 
Inactive Ingredient Database (IID) – An FDA database containing infor-
mation on excipients present in FDA-approved drug products. 
International Nonproprietary Name (INN) – The shortened scientific name 
based on the active ingredient. WHO is responsible for assigning INNs to 
pharmaceutical substances. 
Marketing Authorization (Product License, Registration Certificate) – A 
legal document issued by the competent drug regulatory authority that estab-
lishes the detailed composition and formulation of the product and the pharma-
copoeial or other recognized specifications of its ingredients and of the final 
product itself, and includes details of packaging, labelling and shelf-life. 
Newborn classification based on gestational age (WHO) 
 Term – (37 to 42 weeks of gestation) 
 Late preterm (32 to <37 weeks of gestation) 
 Very preterm (28 to <32 weeks of gestation) 
 Extremely preterm (22 to <28 weeks of gestation) 
New Excipient – An excipient used for the first time in a drug product or a new 
route of administration. Equivalent to “Novel Excipient”. 
No Observed Adverse Effect Level (NOAEL) – The highest dose of a 
substance that, in a given toxicity test, causes no biologically significant effects 
in the exposed test animals. 
Pharmaceutical Alternatives – Products are pharmaceutical alternative(s) if 
they contain the same molar amount of the same active pharmaceutical 
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moiety(s) but differ in dosage form (e.g. tablets versus capsules), and/ or 
chemical form (e.g. different salts, different esters). Pharmaceutical alternatives 
deliver the same active moiety by the same route of administration but are 
otherwise not pharmaceutically equivalent. They may or may not be bio-
equivalent or therapeutically equivalent to the comparator product. 
Pharmaceutical Equivalence – Products are pharmaceutical equivalents if they 
contain the same molar amount of the same API in the same dosage form if they 
meet comparable standards, and if they are intended to be administered by the 
same route. Pharmaceutical equivalence does not necessarily imply therapeutic 
equivalence, as differences in the excipients and/ or the manufacturing process 
and some other variables can lead to differences in product performance. 
Risk Assessment – A systematic process of organizing information to support a 
risk decision to be made within a risk management process. It consists of the 
identification of hazards and the analysis and evaluation of risks associated with 
exposure to those hazards. 
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1. INTRODUCTION 
“Doctors are men who prescribe medicines of which they know little, to cure 
diseases of which they know less, in human beings of whom they know nothing.” 
(Voltaire; 1694–1778) 
 
Medicines contain active pharmaceutical ingredients (API) and a range of 
“other chemicals” known as pharmaceutical excipients. Hundreds of different 
excipients are used in manufacturing process to improve the quality, stability, 
bioavailability, and patient acceptability of medicines.1 Benefits of medicines 
will not be possible in the absence of excipients in many cases. They function as 
diluents, fillers, solvents, emulsifiers, binders, lubricants, glidants, sweeteners, 
preservatives, and flavouring or colouring agents and make up, on average, 
about 90% of each product.2 Therefore, administration of medicines usually 
entails exposure to pharmaceutical excipients. 
Most pharmaceutical excipients are recognized as safe. However, increasing 
number of adverse reports from single excipients raises concerns particularly 
for the most vulnerable groups of patients, i.e. children and especially neo-
nates.3–6 Excipients have undergone exhaustive short- and long-term studies for 
toxicological endpoints in adult population but not in pediatric subpopulations. 
It is known that neonates handle some excipients differently from older age 
groups7 – excipients have been associated with significant adverse events, in-
cluding death, when safety data have been extrapolated from adult data.8–10 
Many of the physiological processes governing absorption, distribution, meta-
bolism and elimination (ADME) of drugs are immature/ different in neonates.11 
Furthermore, recent research in paediatrics and developmental toxicology has 
elaborated the concept of “windows of vulnerability”12 – critical periods in early 
development when exposures to even minimal doses of toxic chemicals can 
disrupt organ formation and cause lifelong functional impairments.13 
If excipients cause or are likely to cause harm in neonates, age-appropriate 
formulations without specific excipients should be developed. From an eco-
nomic point of view, age-appropriate neonatal formulations should be limited to 
those that are absolutely needed. Here, a full understanding of the presence of 
specific excipients in drug products administered to neonates and the extent of 
neonatal exposure to these excipients is a cornerstone. However, there is in-
sufficient information about the risks generated by excipient exposure because 
systematic surveys have not been performed. Although some excipient exposure 
data in neonates are available and raise concerns, these are limited to single/ 
couple of country(s)/ unit(s)/ excipient(s).14–16 For instance, Lass et al. have 
shown that almost all neonates have received potentially harmful excipients in 
two tertiary care hospitals in Estonia.15 No understanding of the Europe-wide 
situation exists, yet it is essential/ warranted to recognise the extent as well as 
the seriousness/ severity of the issue. Targeting large multi-country populations 
should be preferred to reach market sizes of interest to achieve reformulation 
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and substitution where needed. Such approach may also provide a basis for 
suggestions about product substitution, where products free of unwanted 
excipient(s) are available, without the need for expensive reformulation process. 
 
The unique feature of excipient studies is that the use of excipients varies 
considerably between formulations of the same API. This means that to assess 
the exposure to excipients, information about medicines use need to be gathered 
in a way that captures data about API, manufacturer, dosage form, and trade 
name of the formulation to identify the specific product used. When the data 
have to be quantified dosing regimens and individual demographic data should 
also be collected. Here, different observational cross-sectional study designs can 
be implemented. However, little is known about the effect of study design in 
excipient exposure studies. Large international studies are almost entirely 
missing. Accordingly, the methodological aspects have not been addressed. 
 
Excipient exposure study including neonatal exposure to potentially harmful 
excipients in Estonia has been conducted in Tartu University by J. Lass. 
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2. REVIEW OF THE LITERATURE 
Neonates are the group of children under 28 days of age,17 divided into term (37 
to 42 weeks of gestation), late preterm (32 to <37 weeks of gestation), very 
preterm (28 to <32 weeks of gestation), and extremely preterm (22 to <28 
weeks of gestation) neonates.18 Neonates at different stages of maturity/ 
immaturity, particularly very and extremely premature ones, but also late pre-
term and term newborns may have serious medical problems requiring exten-
sive interventions.19–21 In preterm neonates age-specific pathologies include sur-
factant-deficient lung disease, bronchopulmonary dysplasia, patent ductus 
arteriosus, necrotizing enterocolitis, retinopathy of prematurity, intraventricular 
haemorrhage, and periventricular leucomalacia. Term neonates may present 
with hypoxic ischaemic encephalopathy, persistent pulmonary hypertension of 
the newborn, meconium aspiration or congenital structural or functional 
anomalies.22 All neonates have age-specific immune dysfunction which makes 
them vulnerable to a range of infections.23 
A huge number of different medicines are used in neonates,19 that are essen-
tial for the treatment of both acute and chronic illnesses. While the need for 
medicines in neonates is indisputable, up to 90% of medicinal products are used 
unauthorised or off-label in this population worldwide.18,24–29 It means that most 
medications administered to neonates lack convincing data to support their safety 
and efficacy. These drugs have been developed for adults or older children and 
contain excipients thought to be safe in these age groups.10 It has been 
anticipated, that excipients that have not caused problems in older age groups 
can be assumed to be safe in neonates unless there is biological evidence to the 
contrary. Response to pharmaceutical agents is dependent on multiple factors, 
including but not limited to differences in metabolic capacity and organ system 
development.30 Although extrapolation of efficacy from adult to paediatric 
population is feasible for some medicines, supportive paediatric data like 
pharmacokinetic (PK) data and safety information are still required.31 
 
 
2.1 Requirements to paediatric/ neonatal medicines 
As the choice of formulation depends on the condition to be treated and the 
clinical status of the newborn, age-appropriate formulations and strengths using 
appropriate excipients must be developed/ made available.18 The importance of 
using age-appropriate formulations has been acknowledged by all stakeholders. 
As stated in the European Medicines Agency (EMA) “Reflection paper on the 
formulations of choice for the paediatric population”,10 in the more recent draft 
“Guideline on pharmaceutical development of medicines for paediatric use”,32 
as well as in the World Health Organization (WHO) document “Points to con-
sider in pharmaceutical development of pediatric medicines”,33 an ideal dosage 
form for paediatric patients of all ages should allow both safe and accurate dose 
administration in multiple/ various conditions and settings. Even if clinical 
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efficacy and safety have been sufficiently documented for the paediatric 
population as a group, clinical studies may not have sufficient power to detect 
differences in subgroups within the studied age interval. 
Developing a medicine for children/ neonates poses a variety of challenges 
including physiological and biological maturation, swallowing difficulties and 
low tolerance to unacceptable taste.34,35 Several requirements have been identi-
fied as key in the identification of a preferred paediatric dosage form.36 De-
sirable attributes of a paediatric dosage form include:33,36 
 
1. Minimal administration frequency 
2. Minimal impact on lifestyle 
3. Convenient, easy, reliable administration 
a. Acceptable and palatable dosage form (e.g. syrups and suspensions instead 
of traditional solid forms, e.g. tablets) 
b. Minimal requirement for complex calculations for prescribing, dis-
pensing, and administration 
c. Minimal manipulation by health care professionals, parents or caregivers 
4. Dose and dose volume/weight adjusted to the intended age group 
a. Soluble in small volumes 
b. Parenteral preparations should contain small dose volumes, at the same 
time being administered via small needles or cannulas 
5. Transportable and low bulk/weight 
6. Easily produced, stable in variety of climates 
7. Affordable in terms of costs 
8. Commercially viable 
9. Minimal, non-toxic excipients 
 
Appropriate choice of excipients is indispensable for the implementation of all 
the above-mentioned requirements. 
 
 
2.2 Pharmaceutical excipients 
“Excipere” is a latin word meaning “to mix”, “to gather”1 or “other than”.2 In 
1957, excipients were defined as substances used as a medium for giving a 
medicament, that is to say with simply the functions of an inert support of the 
active principle(s).37 In 1974 they were described as “any more or less inert 
substance added to a prescription in order to confer a suitable consistency or form 
to the drug: a vehicle”.37 Nowadays the International Pharmaceutical Excipients 
Council (IPEC) defines an excipient “as any substance other than the active 
drug or pro-drug that is included in the manufacturing process or is contained in 
a finished pharmaceutical dosage form”.38 
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Historically, because of their lack of targeted pharmacological action, 
excipients have been considered inert agents and their importance has been 
largely underestimated.1 In the past, excipients were derived from materials of 
natural origin and employed in the pharmaceutical field in original form, 
without further processing to improve their chemical or physical characteristics. 
Analytical tests conducted by pharmaceutical industry were limited and in-
sufficient to characterise excipients’ quality, even less their safety and func-
tionality.39 However, as early as 1950 T.G.Randolph called attention to the 
problems of excipients in medicines. He suggested that manufacturers change 
their excipients to less allergenic substances and state the composition of the 
“inert ingredients”.40 The traditional concept of excipient has undergone con-
siderable evolution: from simple, chemically and pharmacologically inert vehicle 
to essential adjuvant, guaranteeing and optimising the performance of a modern 
medicinal product.39 
 
 
2.2.1 The role of pharmaceutical excipients in medicines 
Excipients contribute to the performance of the drug to improve safety, bio-
availability, and efficacy of the final formulation.39 The properties of the final 
dosage form are, in the most part, highly dependent on excipients.41 Excipients 
(1) aid processing of the system during manufacture, (2) protect, support, or 
enhance stability, bioavailability, or patients acceptability,35 (3) assist in product 
identification, and (4) enhance any other attribute of the overall safety and 
effectiveness of the drug delivery system during storage and use.42,43 
One of the paradoxes of pharmaceutical formulation science is that, although 
excipients do not treat the disease, the disease cannot be treated without them.44 
Most bulk APIs are not useful to the patient until they are formulated into a 
medical product, and that would not be possible without excipients.44 Excipients 
are required to overcome the chemical, physical, and microbiological challenges 
posed by developing a (paediatric/ neonatal) formulation to achieve a pre-
dictable therapeutic response. Almost all pharmaceutical design aspects are in 
direct relation to the excipients (Figure 1).45 
The concept of “functionality”, introduced recently, means adding excipients 
in order to enhance performance, quality, and safety profile of medicinal pro-
duct.39,46 For example, liposomal amphotericin reduces exposure of renal tubular 
cells and subsequent toxicity.47 In some cases, excipients are essential to ensure 
the stability of the API and/ or to optimise the delivery or the kinetics of the 
API and therefore have a substantial effect on bioavailability.43 
Accordingly, it alludes to excipients having a purpose, which contrasts with 
the old terminology of “inactive ingredients” which hints at the property of 
inertness.46 
 
17 
 
Figure 1. Pharmaceutical design aspects (adapted from Riet-Nales et al., 2016)45 
 
 
2.2.2 Classification of excipients 
Excipients can be classified in different manner, e.g. based on type (standard, 
mixed or co-processed excipients), origin (animal, vegetable, mineral or synthetic 
sources), chemical class (alcohols, carboxylic acid, carbohydrates, dyes, esters, 
glycerides, halogenated hydrocarbon derivates, organic mercurial salts, phenolic 
compounds, proteins or polymers), and functions excipients perform in the 
formulations.48,49 The most appropriate from the clinical point of view and 
therefore often used classification is based on the function – excipients are sub-
divided into various functional classes, depending on the role that they are 
intended to play in the resultant formulation (Table 1). 
Certain excipients can have different functional roles in different formu-
lation types and its concentration may vary depending on the purpose of use. 
For example, propylene glycol can be used as a solvent, antimicrobial preser-
vative, humectant, stabilising agent, or plasticiser.41 
 
  
excipients 
in 
formulation
route of 
administration
dosing 
frequency
product 
appearance
user 
instruction
administration 
device
packaging
type of dosage 
form
active 
substance (salt 
or base)
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Table 1. Classification of excipients by function (modified from Chaudhari and Patil, 
2012)48 
Excipient category Function in formulation Examples* 
Diluents Fillers, bulking agents Lactose, sorbitol, starch 
Binders Adhesives Acacia, gelatin, povidone 
Lubricants Reduce inter-particular 
friction 
Talc, surfactants, stearic acid 
Glidants Improve flow characteristics 
of powder mixture 
Colloidal silicon dioxide, corn 
starch 
Disintegrants Facilitate disintegration after 
administration 
Starches, cellulose, clays 
Coating materials Protect tablet ingredients Povidone, beeswax, acacia 
Solvents Dissolving solute/ API Water, ethanol, acetone 
Co-solvents Increase the solubility of 
solute in solvents 
Ethanol, sorbitol, propylene 
glycol, glycerin 
Buffers Maintain pH Phosphate buffers, acetate 
buffers 
Antimicrobial 
preservatives 
Prevent microbial growth Benzyl alcohol, parabens 
Antioxidants Control oxidation Ascorbic acid, tocopherols 
Wetting agents Aid wetting and dispersion of 
hydrophobic APIs 
Sodium lauryl sulphate, 
lecithins, polysorbates 
Antifoaming agents Discourage formation of foam Simethicone, alcohols 
Thickening agents Prevent settling/ 
sedimentation 
Methylcellulose, 
microcrystalline cellulose 
Humectants Retard evaporation of aqueous 
vehicles 
Propylene glycol, glycerol 
Chelating agents Protect from catalysis Disodium EDTA, citric acid 
Emulsifying agents Prevent coalescence Sodium lauryl sulphate 
Flocculating agents Prevent caking Starch, sodium alginate 
Sweeteners Impart sweetness Sorbitol, saccharin, sucrose 
Coloring agents Aesthetic appearance, product 
identification 
Amaranth, erythrosine, eosin, 
titanium dioxide, carotene 
Flavours Impart flavour Aromatic waters, syrup, 
menthol, orange 
*Excipients that is of interest in this thesis are shown in bold 
EDTA, ethylenediaminetetraacetic acid 
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2.2.3 Pharmacological principles of excipients in neonates and adults 
PK include parameters of ADME and determine the relationship between the 
exposure and body concentration.30 In terms of physiological and anatomical 
factors the neonate has to be considered as a “unique drug recipient”.1,50,51 For 
all the specific variables of the drug kinetics (absorption, blood esterase activity, 
body water and lipid ratios, plasma protein binding, organ perfusion rates, 
metabolic degradation and elimination), there are clear differences between 
neonates and older infants and children not to mention adults.13,50,52,53 
Drug pharmacodynamics (PD), i.e. biochemical and physiologic effects 
exerted in the body, may also vary in neonates in terms of drug-receptor inter-
actions, receptor number, receptor affinity, and receptor regulation and modu-
lation.54–56 In combination with altered PK, this may influence the therapeutic 
and toxic effects of pharmaceutical product significantly.54 Still, there is a lack 
of tools to assess PD effects in neonates and little information exists about the 
effect of human ontogeny on interactions between drugs and receptors and the 
consequence of these interactions.55,56 
 
Singularity of neonatal PK/ PD in relation to excipients. Anatomical, physio-
logical, and biochemical changes that occur from birth as well as any pathologic 
condition affecting the newborn influence PK/ PD of drugs as well as excipi-
ents.57,58 In developmental pharmacology this immaturity is well documented as 
influencing the dose of drugs administered to neonates but less well described is 
the effect on the handling of pharmaceutical excipients.59 
For enteral medicines, the variability in gastric pH, prolonged rate of gastric 
emptying, immaturity of the intestinal mucosa, and decreased first-pass metabolic 
capacity may predispose newborns to higher oral bioavailability and systemic 
concentrations for some chemicals.34,51,52,60–62 Decreased levels of serum binding 
proteins,63 but also the presence of increased serum fatty acid and bilirubin 
levels, can increase the unbound fraction of excipients.52,60 
Higher relative amount in combination with immature metabolic/ elimination 
pathways64,65 may lead to the saturation of metabolism and accumulation of an 
excipient.66 Hydroxylating activity63 and conjugation with glucuronic acid 
(glucuronidation)65,67 appear to be the two metabolic pathways which are the most 
defective at birth, while sulphate68 and glycine conjugation and dealkylation 
activities are close to the adult pattern.50,69 Cytochrome P450 content in neo-
nates is 50% that of adult levels. Tran et al. reported estimated alcohol dehydro-
genase content to be about 10-fold lower in perinatal period compared to adults.70 
Renal elimination is also reduced in neonates due to immature glomerular 
filtration, tubular secretion and reabsorption.71,72 As a result, both renally- and 
hepatically-cleared pharmaceuticals may exhibit longer half-lives.73,74 
Early postnatal period includes the primary developmental events of the 
central nervous system and is extremely susceptible to certain neurotoxins such 
as propylene glycol and ethanol.75 Neonates may have proportionately higher 
brain levels of circulating chemicals due to a higher brain to body weight 
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ratio,76 lower levels of plasma proteins, and the fact, that molecules that enter 
the cerebrospinal fluid and brain during early development are cleared more 
slowly and will accumulate to a greater extent than later in development.77 
Simultaneous administration of multiple excipients metabolised/ eliminated 
through the same immature pathways may further increase the accumulation of 
potentially toxic substrates.9 For example, propylene glycol accumulation may 
occur when administered in combination with another substrate of alcohol 
dehydrogenase (limiting step of metabolism) such as ethanol.9 
 
Accumulation of propylene glycol in neonates following repeated adminis-
tration was demonstrated.78,79 The initial renal elimination of propylene glycol 
in (pre)term neonates is 15% of total clearance compared to 45% in adults.80 
Potential accumulation/ toxicity of propylene glycol is also affected by the 
activity and saturation of alcohol- and aldehyde dehydrogenase.66 The Du et al. 
study confirmed that significant propylene glycol concentrations may be ob-
tained in the brain (up to ~ 0.456 mg/g tissue) following a single dose of 
1 mg/kg in rats.81 In the Kelner and Bailey study with five patients receiving 
medications containing propylene glycol, the cerebrospinal fluid concentrations 
of propylene glycol were as high as 85% of the serum concentrations.82 
The fact that PK may also have great variations within the neonatal popu-
lation in relation to the developmental age of the newborn was confirmed by De 
Cock et al. who showed that birth weight and postnatal age are the most 
important covariates for clearance of propylene glycol in neonates.78 
 
Benzyl alcohol is metabolised to benzoic acid for further detoxification through 
glycine conjugation to form hippuric acid.83 The availability of glycine is the 
rate-limiting factor in the formation of hippuric acid.84 Although the glycine 
conjugation pathway is relatively mature in term newborns, preterm neonates 
are unable to conjugate benzoic acid efficiently.7,10,85 The main safety concern 
with benzoic acid is its ability to displace bilirubin from albumin.86 This risk 
exists with oral, parenteral, and topical formulations. The hazard/ risk of 
developing kernicterus is also to be considered when benzyl alcohol is used 
since benzoic acid is one of its metabolites. LeBel et al. showed a smaller 
amount of hippuric acid in the urine of premature neonates compared with term 
newborns after exposure to benzyl alcohol, indicating that hippuric acid 
formation is deficient in given patients.7 
 
Para-hydroxybenzoic acid (PHBA), the principal metabolite of parabens, may 
be conjugated with glycine or sulfate (maturity is close to the adult levels) and 
glucuronic acid (immature in neonates) for further renal elimination. In prin-
ciple, one more mature metabolic pathway might compensate the immature one. 
However, higher proportions of free parabens were determined in urinary spot 
samples from preterm neonates compared to adults, still showing the prevalence 
of metabolic immaturity.87 
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2.3 Safety of pharmaceutical excipients  
in children and neonates 
“As to diseases, make a habit of two things – to help, or at least, to do no 
harm.” (Hippocrates; ca. 460 BC – ca. 370 BC) 
 
Safety is one of the most important requirements (besides quality and efficacy/ 
functionality) of the pharmaceutical compound including excipients.37 
 
 
2.3.1 Disasters with pharmaceutical excipients 
The inclusion of excipients with inadequately studied safety profile in medi-
cines has resulted in several disasters (Table 2). 
 
Table 2. Paediatric excipient disasters (modified from Choonara and Rieder, 2002)89 
Year Drug Excipient Deaths Country 
1937 Sulphanilamide 
elixir 
Diethylene glycol 
used as solvent 
105 USA 
1970 Bathing foam Contained 
hexachlorophene 
Significant number of 
neonates developed 
neurotoxicity 
USA 
1972 Talc baby powder Contained 6.3% 
hexachlorophene 
36 France 
1982 Sodium chloride 
Water 
Benzyl alcohol 16 USA 
1984 Vitamin E Polysorbate 80 38 USA 
1992 Paracetamol Diethylene glycol 
used as solvent 
47 Nigeria 
1995 Paracetamol Diethylene glycol 
used as solvent 
51 Bangladesh 
1998 Paracetamol Diethylene glycol 
used as solvent 
85 Haiti 
2006 Cough syrup Glycerine 
contaminated with 
diethylene glycol 
46 Panama 
2008 Teething formula Glycerine 
contaminated with 
diethylene glycol 
84 Nigeria 
 
“…to realize that six human beings, all of them my patients, one of them my best 
friend, are dead because they took medicine that I prescribed for them 
innocently, and to realize that that medicine which I had used for years in such 
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cases suddenly had become a deadly poison in its newest and most modern 
form…” (Letter by Dr. A.S. Calhoun, October 22, 1937)88 Seventy-one adults 
and 34 children died in 1937 after taking an “Elixir Sulfanilamide”; the United 
States (US) Food and Drug Administration (FDA) identified diethylene glycol, 
the excipient used as a solvent, as the killer.88 Unfortunately, one of the earliest 
disasters in modern paediatric drug therapy has been the most repeated (Table 2). 
 
Nowadays, it is clear, that common excipients used in a formulation may have 
an unintended influence on bioavailability/ bioequivalence in children and 
neonatal population.90 The historical assumption that excipients are inactive is 
rapidly fading. Unfortunately, the safety issues of excipients still do not receive 
a proper attention in modern neonatal pharmaceutical care and are not just 
historical events.47 
 
 
2.3.2 Types of excipient interactions/ toxicity 
Excipients have the potential to harm patients in two ways. First, by intro-
duction of a chemical (e.g. toxicity, physiological effect) or physical hazard 
(e.g. irritation). Secondly, adversely affecting the API availability or per-
formance (e.g. changes in the bioavailability or modified release).91 Excipients 
have been associated with specific safety issues: allergic reactions, intolerances, 
diminished absorption of API, inhibition of physiological processes, cyto-
toxicity etc.1 Today, it is well known that certain excipients may produce in-
compatibles with the API, another excipient or with intracellular chemicals – 
excipient-drug, excipient-excipient, and excipient-human body interactions.49 
Some examples of different types of interactions are shown in Table 3. 
 
Table 3. Different types of harmful excipient interactions 
Excipient Type of 
interaction 
Description 
Diethylene glycol Excipient-body CNS, renal, and hepatic toxicity75,92 
Benzoic acid/ 
sodium benzoate 
Excipient-drug Pronounced inhibitory effect on the formation 
of salicyluric acid from salicylic acid and may 
result in increased concentration and 
persistence of salicylic acid in the body93 
Ethanol Excipient-excipient Inhibits the formation of hippuric acid from 
benzoic acid94 
Competitively inhibits the metabolism of 
propylene glycol9,95 
Ethanol Excipient-body CNS depressant by binding to the gamma-
aminobutyric acid A receptor96 
CNS, central nervous system 
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2.3.3 Classification based on safety of excipients 
Based on the safety profile excipients were classified by Lass et al. (Table 4) as 
potentially safe, potentially harmful and known to be harmful, and excipients 
with no safety data available or with unspecific description.15 
 
Table 4. Classification of excipients according to the potential safety/ toxicity 
(modified from Lass et al., 2012)15 
Safety status Description Examples 
Potentially safe No ADR reported Citric acid, hydrochloric acid, 
water, starch, simethicone 
Potentially harmful and 
known to be harmful 
ADR reported Propylparaben, benzyl alcohol, 
benzoates, propylene glycol, 
polysorbate 80, ethanol, 
benzalkonium chloride, sorbitol 
No safety data found No data found in the 
literature on human 
exposure and toxicity 
Sodium carmellose 
Description of the 
excipient in SmPC or  
PIL unspecific 
Description does not 
allow a specific  
literature search 
Flavouring agents, coloring 
agents 
ADR, adverse drug reaction; PIL, package insert leaflet; SmPC, summary of product charac-
teristics 
 
 
2.3.4 Potentially harmful excipients in neonates 
Today, we have well established (does not mean exhaustive) safety databases 
on existing excipients, and new excipients are required to undergo extensive 
animal safety testing before they can be used in clinical studies.97 For some 
excipients, there are data to support “safe” exposure levels in adults. However, 
the safety profile of some common excipients (Table 4; Table 5) may differ 
between children and adults as well as across the various paediatric sub-groups. 
Excipients that have been highlighted as having a potential to cause toxico-
logical problems in neonates are shown in Table 5. These are referred to as 
excipients of concern or problematic excipients or excipients of interest (EOI) 
for this thesis. 
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Table 5. Excipients with reported adverse effects in neonates and older children 
Excipient Reported adverse effects  
 Newborns (<28 days old) Children >28 days old 
Propyl-
paraben 
Hyperbilirubinemia, hypersensitivity 
reactions, (oestrogenic effects)41,98 
Allergic reactions, 
bronchospasm98 
Polysorbate 
80 
E-Ferol syndrome – thrombo-
cytopenia, renal dysfunction, 
hepatomegaly, cholestasis, ascites, 
hypotension, metabolic acidosis41 
Hypersensitivity following 
topical and intramuscular use41 
Propylene 
glycol 
Skin irritation, CNS depression, 
cardiovascular, hepatic, respiratory 
adverse events, hyperosmolality; 
lactic acidosis1,41,98 
Large volumes associated with 
adverse effects most commonly 
on the CNS41 
Benzyl 
alcohol 
Metabolic acidosis, seizures, gasping, 
intraventricular haemorrhage, 
kernicterus, fatal toxic 
syndrome1,41,85,98,99 
May cause toxic and allergic 
reactions in children up to 
3 years old98,100 
Benzoic acid, 
sodium 
benzoate 
Hypersensitivity, kernicterus41,86,98 Skin, eye, and lung irritation, 
urticaria, angiooedema98 
Saccharin 
sodium 
Urticaria, photosensitivity 
reactions101 
Generally regarded as safe;  
skin hypersensitivity41 
Sorbitol Diarrhoea, nutrient malabsorption, 
diabetic-like symptoms49,102 
Mild laxative effect98 
Ethanol Lactic acidosis; hypoglycaemia;  
CNS effects1,41,103 
Harmful for those with liver 
disease or epilepsy; skin 
irritation; may alter the effects 
of other medicines; 
hypoglycaemia; CNS 
effects96,98,103  
Benzal-
konium 
chloride 
Ototoxic when applied to ear, skin 
irritation and hypersensitivity, eye 
irritation1,41,98 
Skin and eye irritation, 
bronchospasm98,104 
CNS, central nervous system 
 
2.3.4.1 Safety of EOI and current implications 
The amount usually plays a critical role in safety/ toxicity of excipient in 
formulation. Maximum tolerated doses for excipients, determined by animal 
safety testing, are usually referenced for use in adults and are not necessarily 
applicable to their use in children and particularly in neonates. Furthermore, 
even in adults saturation of metabolic clearance of e.g. propylene glycol occurs 
at lower doses (0.2 g/kg) than in rats and rabbits (2 g/kg),66 indicating the 
imperfection of animal safety studies. While acceptable daily and cumulative 
intake of excipients is not clearly defined for different paediatric age groups, 
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some excipients, e.g. benzyl alcohol, should be totally avoided in neonates.83 
Fortunately, existing clinical data and comprehensive set of non-clinical data 
have allowed estimating the acceptable daily intake (ADI) and no observed 
adverse effect levels (NOAEL) for some excipients that are of interest in this 
thesis (Table 6).  
Table 6. Acceptable daily intake (ADI) and no observed adverse effect level (NOAEL) 
of EOI 
Excipient ADI NOAEL Comments 
Propylparaben87 2 mg/kg 100 mg/kg Applicable to all ages including 
neonatal period 
Polysorbate 
80105,106 
10 mg/kg calculated as 
total polysorbate esters
1000 mg/kg No neonatal data 
E-Ferol syndrome in preterm 
neonates 
Propylene 
glycol66,107 
1 mg/kg (neonates) 
50 mg/kg (< 5 years) 
500 mg/kg (adults) 
192 mg/kg 
(term neonate)
150 mg/kg  
(1-year child) 
126 mg/kg  
(4-year child) 
Co-administration with any 
substrate of alcohol 
dehydrogenase such as ethanol 
may induce serious ADRs in 
neonates 
Benzyl  
alcohol41,98,100,108 
Should not be used in 
neonates 
5 mg/kg (adults, 
WHO) 
Subchronic 1 mg/kg; 
chronic 0.3 mg/kg 
(adults, EPA) 
Not specified No paediatric data 
“Gasping syndrome” observed 
in neonates. May cause toxic 
and allergic reactions in children 
up to 3 years old 
Benzoic acid, 
sodium 
benzoate86 
5 mg/kg (sum of all) 500 mg/kg No neonatal data 
Inhibitory effect on the 
formation of salicyluric acid 
from salicylic acid 
Displace bilirubin from albumin 
Saccharin 
sodium41 
2.5–5 mg/kg Not specified No neonatal data 
Sorbitol41 Not specified (< 20 
g/day in adults) 
Not specified No paediatric data 
Ethanol33,103 Blood ethanol levels 
should not exceed 25 
mg/dL (AAP)/ 1 
mg/dL (EMA) after a 
single dose (or a dose 
of 6 mg/kg) in children 
younger than 6 years 
Not specified CNS effects at 10 mg/dL 
Benzalkonium 
chloride 
Not specified Not specified As residue in food 0.1 mg/kg 
AAP, American Academy of Pediatrics; ADR, adverse drug reaction; CNS, central nervous 
system; EMA, European Medicines Agency; EOI, excipient of interest; EPA, Environmental 
Protection Agency; WHO, World Health Organisation 
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Propylene glycol is commonly used as an excipient in a variety of drugs and it 
is also authorised in food products and cosmetics. While it is generally con-
sidered safe as a food additive, concerns have repeatedly been raised about po-
tential toxicity of propylene glycol and its acidic metabolites following pharma-
cologic exposure.66 High doses of propylene glycol in neonates may result in 
both biochemical (e.g. hyperosmolarity, lactic acidosis, plasma creatinine, bili-
rubin) and clinical (cardiovascular, central nervous system (CNS), renal, res-
piratory, hepatic, hematologic) toxicity.95,107 For example, Peleg et al. reported a 
case of propylene glycol intoxication in a premature infant. The infant went into 
a state of coma after treatment for burns with antiseptic dressings containing 
propylene glycol. Cessation of the topical treatment resulted in complete re-
covery. High peak of propylene glycol was measured in urine.6 MacDonald et 
al. showed that neonates receiving 3000 mg/day of propylene glycol as a vehicle 
in an intravenous multivitamin preparation had a higher incidence of seizures 
than those receiving 300 mg/day in a different vitamin preparation.114 Clinical 
data showed that in children from the age of 5 years and adult patients, up to 
500 mg/kg/day of propylene glycol could be considered safe.107 In MacDonalt 
et al. study neonates receiving 300 mg/day of propylene glycol had a higher risk 
of developing hyperosmolality compared with neonates not exposed.114 There-
fore, EMA decreased the safety threshold for propylene glycol to 50 mg/kg/day 
in children less than five years old, and even to 1 mg/kg/day in preterm and 
term neonates.107 
 
Ethanol has been commonly used for years in paediatric and neonatal liquid 
formulations as a solvent and preservative despite the lack of safety, PK, and 
PD data. Ethanol acts as a CNS depressant by binding to the gamma-amino-
butyric acid A (GABA-A) receptor and by increasing the inhibitory activity of 
the neurotransmitter GABA.96 Other ethanol related toxicities in children 
include hypoglycemia, acidosis, respiratory depression, seizures, hypothermia, 
and electrolyte abnormalities.115 
Newborns and infants are at higher risk of both acute and chronic alcohol-
related toxicities, e.g. some ethanol containing furosemide and iron formu-
lations are given to the premature newborns for months.96 Recently, Svirskis et 
al. identified 47 paediatric liquid medicines in New Zeland containing ethanol 
and indicated for both acute and chronic use in patients of all ages including 
preterm neonates.116 In 1999 Fiocchi et al. found 103 drug products containing 
ethanol for prescription in children, each of which was able to deliver a theo-
retical blood concentration more than 20 mg/dL.117 
Ethanol may cause lasting defects in cognition and behavior in neonates where 
neuronal differentiation, myelination, and migration are not fully developed.76 
Toxicity on brain maturation in neonates is also supported by non-clinical data.33 
As well, chronic exposure has been shown to be linked to dependence in adoles-
cents and adults.33 Additionally, ethanol inhibits the formation of hippuric acid 
from benzoic acid,94 slowing the metabolism of another potentially harmful 
excipient (Table 5). Moreover, when administered concomitantly with propylene 
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glycol, ethanol has a 10 to 20 times greater affinity for alcohol dehydrogenase 
and therefore competitively inhibits the metabolism of the former and may lead 
to elevated/ toxic concentrations of propylene glycol.9,95 In 2011 the US FDA 
notified healthcare professionals of serious health problems that have been 
reported in premature babies receiving Kaletra (lopinavir/ ritonavir) oral 
solution.9 This solution contains ethanol (42,4% v/v or 356 mg/ml) and pro-
pylene glycol (15,3% w/v or 152,7 mg/ml) in significant amounts. The con-
sequences of administering such amounts of these excipients can be severe or 
possibly fatal – toxicity related to Kaletra oral solution included hyperosmo-
lality with or without lactic acidosis, renal toxicity, CNS depression (including 
stupor, coma, and apnea), seizures, hypotonia, cardiac arrhythmias, electro-
cardiographic changes, and hemolysis.9 Given toxicity was linked to excipients. 
It remains unclear what ethanol exposure is safe for neonates.118 Chronic 
exposure to ethanol (> 1 week), even in small doses, through pharmaceutical 
product is in principle contraindicated below six years of age and limited to two 
weeks above six years.33 Adverse CNS effects are already reported with blood 
ethanol concentrations of 10 mg/dL in children.33 Therefore the EMA recom-
mendation103 regarding blood ethanol level after a single dose in children younger 
than six years (Table 6) seems to be more expedient compared to the American 
Academy of Pediatrics (AAP) Committee on Drugs.119 
 
Bactericidal preservatives like benzalkonium chloride are frequently found in 
beclomethasone and ipratropium bromide nebuliser solutions and can cause 
paradoxical bronchoconstriction in asthmatic children.3,104 Padnos et al. described 
a 3-month old infant hospitalised for croup and underwent placement of tracheo-
stomy tube, which could not be removed for three months because of the occur-
rence of difficulties in breathing, coughing spasms and development of severe 
cyanosis upon repeated attempts of extubation. The cause of respiratory difficulty 
was a severe haemorrhagic dermatitis of tracheal mucosa at the tracheostomy site 
as a reaction to the benzalkonium chloride solution used for disinfection.120 Ben-
zalkonium chloride has also been associated with ototoxicity and ophthalmo-
logical problems (conjunctivitis, corneal injury).40 There are no data on ADI for 
benzalkonium chloride available. 
 
The use of sweeteners and flavouring agents is particularly important in pae-
diatrics to improve palatability.1 The use of carbohydrates with the potential to 
raise plasma glucose such as fructose, glucose, or sucrose should be limited or 
avoided in diabetic children. Sorbitol can be used as a sweetener, humectant, 
and vehicle for oral and topical pharmaceutical liquids and therapeutically as an 
osmotic laxative/ cathartic. Including sorbitol in formulation as an excipient 
(sweetener) may entail such adverse drug reactions (ADR) as diarrhoea and 
malabsorption particularly in neonates.121 The accumulation of sorbitol in the 
body has been implicated in diabetic-like symptoms like retinopathy in neo-
nates.49 The recommendation for ADI of sorbitol in children is not available. 
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Some allergic reactions have been associated with flavouring agents, the 
problem being the lack of data on exact composition of these complex mixtures, 
which may complicate the safety assessment.122 Napke and Stevens described a 
few cases of severe abdominal pain, nausea, and vomiting following adminis-
tration of erythromycin containing tincture of orange; the youngest patient was 
a 6-week old infant.123 Substitution of given formulation with another formu-
lated with cherry syrup resolved the problem immediately and completely. At 
that time (1984) the pharmacist responded as have many practitioners in the 
past: “The active ingredient is the same; the colouring and flavouring do not 
matter.”123 
 
Fortunately, in recent years some new data have appeared providing the safe use 
of e.g. methyl hydroxybenzoate (methylparaben, MPB) in every age group 
including neonates. Parabens belong to a family of antimicrobial preservatives 
that are widely used in cosmetic, pharmaceutical, and food industries. During 
the last decade parabens have been extensively studied to evaluate male repro-
ductive toxicity124 because of the reports of weak in vitro estrogenic activity 
being between 10,000 to 100,000 fold less potent than that of oestradiol.125 Oishi 
suggested that propyl hydroxybenzoate (propylparaben, PPB) adversely 
affects the hormonal secretion and the male reproductive function in rats – 
decreased testosterone concentration, sperm production and efficiency;126 at the 
same time MPB and ethylparabens did not show any adverse effect on the 
secretion of sex hormones or the male reproductive function.127 Recent toxicity 
study conducted according to Good Laboratory Practice in an appropriate and 
statistically robust manner failed to reproduce the effects of PPB on repro-
ductive function observed by Oishi.128 This study showed an absence of toxic 
effects on the maturation of the male reproductive system, up to the highest 
dose of 1000 mg/kg/d of PPB, thus not indicating any endocrine disrupting 
potential.128 These results were confirmed in another juvenile toxicity study 
conducted by Pouliot et al. and using rats treated from the neonatal period. 
(unpublished, referenced from EMA reflection paper87) Thus, in a recent ref-
lection paper, EMA concluded that the use of MPB in oral formulations up to 
0.2% of the product (as within the recommended effective concentrations as a 
preservative) is not a concern for humans including the paediatric population 
whatever the age group. Regarding PPB, based on the results from recent 
studies, a conservative “no observed effect level” of 100 mg/kg has been de-
termined with ADI of 2 mg/kg/day for the use in adults and paediatric 
patients.87,129 However, it was considered that the lack of estrogenic effect could 
not be ascertained at the high dose level in females. 
 
Co-administration of different excipients. The number of different medi-
cations administered to a child is the most significant statistical association with 
the risk of ADR.130 Published data show that the average number of drugs 
administered per infant in the neonatal intensive care units (NICU) has progres-
sively increased over the years.131 Polypharmacy may lead to multiple sources 
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of EOI, resulting in additive exposure and/ or interactions in metabolism. 
Ethanol is known to inhibit the formation of hippuric acid from benzoic acid 
(Table 3).94 Benzyl alcohol, in turn, in rats inhibits noncompetitively activity of 
hepatic alcohol dehydrogenase and mitochondrial aldehyde dehydrogenase.132,133 
As excipient toxicity is dose dependent, cumulative exposure is one of the 
several factors determining the likelihood of toxic effects.98 Shehab et al. 
observed a wide range in the cumulative dose of benzyl alcohol and propylene 
glycol from multiple formulations received by neonates with potentially toxic 
doses registered during routine care.134 
 
 
2.4 Exposure to EOI in neonates 
“Excipients in neonatal formulations are never prescribed, but commonly 
administered.” (Karel Allegaert) 
 
According to available studies, several medicines frequently used in neonates 
may contain EOI (Table 7).15 
 
Table 7. EOI in frequently used medicines in neonates15,16,41,116,134,135 
Excipient Function in formulation Drug 
Methyl- and 
propylparabens 
Antimicrobial preservative Gentamicin inj solution 
Heparin inj solution 
Iron oral solution 
Propylene glycol Antimicrobial preservative, 
humectant, plasticizer, 
solvent, stabilizing agent, 
water-miscible cosolvent 
Salbutamol nebulisation solution 
Phenobarbital inj solution 
Lorazepam inj solution 
Diazepam oral solution 
Polysorbate 80 Dispersing, emulsifying, 
solubilizing, suspending, and 
wetting agent, non-ionic 
surfactant 
Epoetin alfa inj solution 
Phenobarbital inj solution 
Budesonide nebilisation solution 
Chloramphenicol opthalmic 
solution 
Miconazole ointment 
Ethanol Antimicrobial preservative, 
solvent, skin penetrant 
Heparin ointment 
Miconazole ointment 
Alprostadil inj solution 
Iron syrup 
OTC products 
Benzyl alcohol Antimicrobial preservative, 
solvent 
Heparin inj solution 
Phenobarbital inj solution 
Midazolam inj solution 
Hydrocortisone inj solution 
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Excipient Function in formulation Drug 
Sodium benzoate Antimicrobial preservative, 
lubricant 
Simethicone oral suspension 
Caffeine solution 
Zidovudine oral solution 
Saccharin sodium Sweetener Simethicone oral suspension 
Iron oral solution 
Nystatin oral suspension 
Sorbitol Sweetener Iron oral solution 
Benzalkonium 
chloride 
Antimicrobial preservative, 
solubilizing agent, wetting 
agent 
Salbutamol nebulisation solution 
Chloramphenicol opthalmic 
solution 
EOI, excipient of interest; inj, injection; OTC, over-the-counter drugs 
 
Neonates admitted to the NICU may be exposed to more than 60 parenteral and 
more than 40 enteral medicines, each of which contains excipients.136 Especially 
preterm neonates may be chronically exposed as a result of being treated with 
several medicines for extended periods. To date, only a few studies of estimated 
neonatal exposure to excipients have been conducted, one of the reasons being 
probably methodology issues. 
 
 
2.4.1 Methods to assess the exposure to excipients 
When planning medicine/ excipient exposure studies the research question to be 
answered needs to be balanced against the implications of study design. In 
principle, the use of medicines has to be studied first, and methods available in 
food safety and pharmacoepidemiology can be applied.137–139 However, infor-
mation required in excipient studies may not be available in multi-country 
databases suitable for drug studies.140 While these data may be available on sales 
level, individual exposures are of relevance. 
 
 
2.4.1.1 Qualitative excipient exposure assessment 
Different observational study designs can be used in pharmacoepidemiology and 
particularly in drug utilisation studies,57,139 not all of them are “perfect” for the 
assessment of excipient exposure. Case-control studies allow rich data col-
lection for a limited number of medicines/ excipients/ patients and may be used 
to describe some e.g. ADR in an individual patient(s); data collection is limited 
to a few centers and therefore is not suitable for comprehensive exposure 
assessment. Cohort studies have the advantage of allowing data collection over 
prolonged time periods24 and therefore can be of particular interest to study rare 
exposures/ outcomes and drug utilisation patterns over time.139 However, the 
expense and duration make it hard to implement in multinational settings.24 
Table 7. Continuation
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Economic evaluation plays a role in the choice of a specific study design. 
There is considerable overlap between acceptable methodologies and those 
sanctioned by health economists.141 Here, cross-sectional studies, also known as 
prevalence studies, are attractive for assessment of medicines use137,142–147 and 
can be used for estimating the exposure to excipients as well. Some advantages 
and disadvantages of different study designs when targeting to estimate excipient 
exposure are summarised in Table 8.  
Table 8. Advantages and disadvantages of different study designs in excipient exposure 
assessment using pharmacoepidemiological methods57,139 
Study design Advantages Disadvantages 
Case-control Allows rich data collection 
Allows investigation of rare 
exposures 
Data collection is limited to a 
few centres 
Drug exposure data collected 
retrospectively 
Cohort design Data can be collected pro- or 
retrospectively 
Allows data collection over 
prolonged time periods 
Allows rich data collection 
Allows estimation of risks 
Allows estimation of rare exposures 
May not be feasible in 
multicentre/ multinational 
settings 
Resource and time-consuming 
In retrospective study data 
quality is questionable 
Cross-
sectional 
Allows multinational studies 
Allows multiple data collection 
Time and resource saving 
Depending on design allows 
individualised approach or data 
collection over prolonged period 
Under- or overestimates 
exposure of rarely used agents 
Depending on design limited 
amount of data or covers very 
short time periods 
Databases 
analysis 
Allows multinational studies 
Allows long-term collection 
Allows individualised approach 
Do not contain data on 
formulation and/ or tradenames 
and/or manufacturers details 
Resource consuming 
 
Cross-sectional studies, often described as “taking a snapshot”, seem to be the 
most appropriate for estimating excipient exposure in neonates because they 
require a relatively shorter time commitment and fewer resources to conduct. 
These studies can explore the role of factors associated with exposure,139 data 
can be collected at the unit or individual level. An example of a unit level cross-
sectional observation is a service evaluation survey (SES). Unit level data indi-
cate which medicines are used (including distinct products, APIs, and excipi-
ents). In combination with demographic data about the units this method can 
provide indicative estimates of market size, that may justify the requirement of 
product reformulation or substitution. Unit level studies can have a longer 
duration but may not be manageable in a multinational setting.24 With large 
volumes of data reported like in excipient studies and especially prolonged 
recall periods decreasing compliance and underestimation may occur.57 Indi-
vidual level data allow for stratification according to important clinical 
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variables such as the age of the newborn, but this approach requires an extra 
step of data collection. Point prevalence studies (PPS) have been used in anti-
biotic consumption studies.145,146,148 Their extremely short duration may un-
derestimate exposure to less frequently used medicines. 
 
 
2.4.2 Excipient exposure studies in practice –  
extent of neonatal exposure to EOI 
There are few data available about the extent to which neonates are exposed to 
excipients (Table 9). Recent observational studies suggest that neonates are 
exposed to significant amounts of excipients including EOI, like ethanol, pro-
pylene glycol, benzyl alcohol, and sorbitol, with the doses occasionally 
exceeding internationally recommended limits of exposure.14,134 
Table 9. Review of excipient exposure studies in neonates 
Reference Study population Study 
duration
Results Country 
Shehab  
et al. 2009134
Randomly selected 
sample of neonates 
from one tertiary care 
hospital exposed to 
BA (n=88) or PG 
(n=82) through 
parenteral medicines 
12 
months 
Median (range) cumulative 
dose was 106.3 mg/kg/day 
(47.5–319.5) for BAa, and 
4554.5 mg/kg/day (869.5–
9472.6) for PGb in neonates 
who received medicines via 
continuous infusion 
USA 
Whittaker  
et al. 200914 
38 preterm neonates 
(< 30 weeks gestation 
and < 1500g birth 
weight) from one 
neonatal unit 
12 
months 
20 excipients identified 
Exposure to ethanol ranged 
from 0.2 to 1.8 ml/week 
Exposure to sorbitol ranged 
from 0.1 to 3.5 g/kg/weekc 
All neonates given 
dexamethasone were 
exposed to PG with a dose 
above 25mg/kg/dayb 
UK 
Lass et al. 
201215 
838 neonates from 
two tertiary care 
hospitals 
12 
months 
123 excipients identified 
88% of neonates exposed to 
EOI 
Estonia 
Souza et al. 
2014135 
79 neonates from one 
neonatal unit 
3 
months 
86 excipients identified 
87% of neonates exposed to 
EOI 
Brazil 
Fister et al. 
201416 
48 neonates from one 
neonatal unit 
1 month 60 different excipients 
identified 
All neonates exposed to 
EOI 
Slovenia 
EOI, excipients of interest; BA, benzyl alcohol; PG, propylene glycol; aBA should not be used in 
neonates; in adults, recommended maximum daily intake is 1–5 mg/kg/day; bthe safety threshold 
for PG in neonates is 1 mg/kg/day; cusing the weight of an average adult male (70 kg) as the 
denominator, the adult recommendations (20 g/day) equate to 2 g. of sorbitol/kg/week 
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Despite the European Union (EU) and the US recommendations and incentives, 
medicines used in neonates still contain excipients with known potential for 
toxicity.32,43,149 Neonates in NICU may be exposed to over 20 different 
excipients per day through only commonly used drugs.14 In Fister et al. study 
from Slovenian neonatal unit every neonate was exposed to the two most 
common excipients known to cause harm to this age group – ethanol and propy-
lene glycol – as these excipients are present in pharmaceutical products recom-
mended for daily antirachitic prophylaxis (vitamin D formulation). Positively, 
neonates in this study were not exposed to benzyl alcohol. In contrast to this, 
Garcia-Palop et al. reported benzyl alcohol to be one of the most common EOI 
in parenteral medicines prescribed to neonates in Spain.150 
 
 
2.4.2.1 Quantitative exposure to EOI in neonates 
Only few studies have tried to quantify exposure of neonates to EOI (Table 9). 
Whittaker et al. reported premature neonates exposed among other excipients to 
ethanol through iron supplements and furosemide, resulting in chronic exposure 
to low doses of ethanol (iron long-term therapy) and acute exposure to high doses 
(management of patent ductus arteriosus).14 Neonates with chronic lung disease 
were concominantly exposed to other EOI contained in dexamethasone – 
benzoic acid, propylene glycol, and sorbitol. All infants receiving dexametha-
sone exceeded the safe limit of propylene glycol14 accepted by WHO41 and 
EMA.66 
Shehab et al. reported the median cumulative doses of propylene glycol 180 
times the ADI according to the WHO criteria.134 Amount of propylene glycol 
administered to neonates during routine care in NICU exceeded the doses above 
which toxicity has been reported in infants. In the same study critically ill neo-
nates on continuous infusions received a median cumulative dose of benzyl 
alcohol 21 times the adult ADI of 5 mg/kg/day.134 
Cordell et al. developed a highly sensitive quantitative method capable of 
detecting ethanol and its metabolites in micro-volume (≤ 100 microlitre) neo-
natal plasma samples left over from hospital testing.151 Further, Pandya et al. 
reported low blood ethanol concentrations in neonates administered iron and/ or 
furosemide but markedly elevated blood acetaldehyde, a potentially toxic meta-
bolite of ethanol, concentrations in some preterm infants receiving these 
medicines.152 
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2.5 Regulatory aspects and initiatives in paediatrics  
in terms of excipients 
“He who studies medicine without books sails an uncharted sea, but he who 
studies medicine without patients does not go to sea at all.” (William Osler; 
1849–1919) 
 
Until recently paediatric drug development was not considered an integral part 
of drug development, some of the reasons being lack of legal requirement to 
perform paediatric studies and ethical dilemma regarding patient recruitment.29 
Nowadays it is realised that children have the right to properly researched and 
regulated medicines, and therefore incentives have been proposed by the EU 
and US regulatory bodies to stimulate paediatric product development.97,153 The 
Regulation on medicinal products for paediatric use (Regulation (EC) 1901/2006) 
creates obligations with regards to conducting clinical trials in paediatric patients 
including neonates.154 The EMA “Guideline on the investigation of medicinal 
products in the term and the preterm neonate” is addressing the impact of im-
maturity of different organ systems and should be relevant to all investigations 
of medicinal products that include participation of the neonatal population.18 
Lately, an increase in paediatric studies was notable resulting in new paediatric 
information in product labeling. In a review of the US FDA databases, Laughon 
et al. identified 28 drug products studied in neonates and 24 resulted in labeling 
changes between 1997 and 2010; only for 11 products changes established 
safety and effectiveness.155 
In the past, the attention of the pharmaceutical industry and the Regulatory 
Authorities was directed mainly to controlling the quality of the API rather than 
that of the excipients; with the approval of drug product came the acceptance of 
the excipient with their inertness and innocuity taken for granted.156 Nowadays, 
according to regulatory requirements from EMA and the US FDA, excipients 
have to be appropriately evaluated for safety.39,43,157–159 However, although the 
US FDA provides guidance for industry on non-clinical studies for the safety 
evaluation of excipients, and the Joint Expert Committee on Food Additives 
evaluates excipients taking into consideration the results of long-term toxico-
logical studies with the publication of an ADI, safe levels of excipients in the 
paediatric and particularly neonatal population are not defined for the majority 
of excipients.160,161 
The presence of each excipient in pharmaceutical formulation must be justi-
fied both in qualitative (functional) and quantitative terms (optimal amount); an 
explanation of the choice of the excipient should be provided.162 Juvenile animal 
toxicity data should be considered when previous animal and human safety data 
are judged to be insufficient to support paediatric use. Warning statements 
relating to the presence of certain excipients in medicinal products have been 
published by EMA in the guideline “Excipients in the label and package leaflet 
of medicinal products for human use”, intended for use by competent authorities, 
applicants for a Marketing Authorisation and Marketing Authorisation Holders.98 
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It provides, that excipients known to have a recognised action or effect, e.g. 
those listed in the Annex to given guideline,98 need to be declared on the labelling 
of all products under a separate subheading qualitatively and quantitatively; any 
adverse reaction specific to excipients should be included.163 Thus, since 2010 
new medicines have to stipulate the quantitative data regarding excipients, listed 
in the abovementioned Annex, in the summary of product characteristics (SmPC). 
However, there is no such obligation for the medicines put on the market before 
2010. Additionally, since the last revision of the guideline in July 2003, several 
safety concerns regarding excipients not currently addressed in the guideline, 
have been identified. For example, the current guideline does not include poly-
sorbate 80 and saccharin sodium. Following the European Commission decision, 
the objective of the Excipients drafting group (ExcpDG) is to update the 
labelling of selected excipients listed in the Annex of the guideline mentioned 
above to encompass pregnant women and children, as well as to add new 
excipients to the list.164 The ExcpDG prepares a questions-and-answers docu-
ment for each excipient under review.86,100,103,107,165 
IPEC is an international industry association formed in 1991 by manufac-
turers and users of excipients.38,166 IPEC’s objective is to contribute to the 
development and harmonization of international excipient standards. According 
to the IPEC guide “Qualification of Excipients for Pharmaceutical Use” pharma-
ceutical formulators should consider the proper use of the excipient – the key 
principle is that of protecting the patient. Although this guide does not address 
children and neonates as a special population, it states that the intended end use 
(e.g. neonatal population) of the excipient should be identified and considered 
in determining appropriate regulatory and Good Manufacturing Practice (GMP) 
requirements for the excipient;166 safety, quality and functionality are the main 
requirements.167 Recently, IPEC-America submitted suggestion that including 
information on paediatric use of excipients would improve the quality of data in 
the US FDA’s inactive ingredients database (IID).168 
The last EU risk assessment guidelines for excipients (2015/C95/02)169 
requires appropriate GMP for all excipients in medicinal products for human 
use to be ascertained by a formalised risk assessment in accordance with ICH 
guideline Q9 on Quality Risk Management (ICH Q9).170 
 
2.5.1 Including EOI into medicines during manufacturing  
process (selection of excipients) 
“Coming together is a beginning. Keeping together is progress. Working together 
is success.” (Henry Ford; 1863–1947) 
 
EMA guidelines state that marketing authorisation applicants and holders should 
ensure that inclusion of excipients into the paediatric/ neonatal formulation is 
justified and the smallest amount is used to achieve the desired function.18 
The selection and use of excipients in paediatric formulations should take 
into consideration the following:32,33,171 
36 
1. The functionality and safety/ toxicity profile across proposed population 
a. Efficiency/ function of excipient in the formulation and potential alter-
natives 
b. Metabolism and elimination pathways of an excipient 
c. Toxicity/ safety in the specific age group 
2. Therapeutic indication, criticality of the condition to be treated and the 
therapeutic alternatives 
3. Dosage regimen i.e. exposure 
a. Acceptable daily intake (acute toxicity) 
b. The frequency of dosing 
c. The duration of treatment (chronic toxicity) 
d. Polypharmacotherapy (additive toxicity) 
4. Route of administration 
 
It is not acceptable to include in a medicinal product an ingredient (excipient) 
that is not genuinely needed, e.g. preservative agents should not be included in a 
sterile single-dose product.172 The feasibility of this approach is well proven by 
the adoption of the AAP recommendation on removal of ethanol from over 700 
liquid preparations for children by industry.59 
As stated by EMA, any risk identified for an excipient would be acceptable 
only on condition that this excipient cannot be substituted with a safer available 
alternative or where the overall benefit/ risk balance for the product outweighs 
the safety concerns.173 If this would not be possible and replacement may raise 
other issues, sufficient development data demonstrating that the lowest concent-
ration of excipient is used, should be established.33,173 For example, a single-
dose injection product should not contain benzyl alcohol as a preservative. 
However, if it is justified with scientific data, the use of benzyl alcohol would 
be allowed in a role of co-solvent for a poorly soluble API. The use of such 
product should be contraindicated in neonates and children up to 3 years old 
because of adverse reaction concerns.46 
 
2.6 Avoiding EOI in neonates 
As discussed above excipients are necessary components of medicines and thus 
hardly can be totally avoided. Multiple situations have been seen over past 20 
years, where contaminated products have caused deaths and serious injuries,174 
indicating that medicines without some specified excipients may not pose the 
gold standard. Most of these tragedies were caused by medicines produced by 
compounding pharmacies,174 pointing again to the urgent need of age-appro-
priate dosage forms and strengths of APIs for the paediatric and particularly 
neonatal population to minimize the manipulations and therefore the risk of 
contamination and medication errors. 
Errors in drug administration is potentially preventable issue that may result 
in toxic concentration of some excipients.33 Errors with potential for harm are 
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three times more likely to occur in paediatric patients and particularly in neo-
nates than in other age groups175 due to the use of inappropriate formulations 
requiring complex calculations and measurement of tiny volumes or multiple 
dilutions.18 As a result, neonates are at risk of unpredictable dosing and side 
effects from potentially harmful ingredients, including excipients.176,177 For 
example, in 2007 a Dear Healthcare Provider Letter informed healthcare pro-
fessionals about lethal overdose of Kaletra oral solution in a preterm neonate, 
given about ten times the calculated volume.178 Another case was reported by 
Masi et al., where after receiving a high loading dose of amiodarone, the new-
born rapidly developed cardiogenic shock and multiple organ failures.5 The 
hypothesis that the two excipients, benzyl alcohol and polysorbate 80, pre-
cipitated the occurrence of the ADRs seems plausible, because the plasma con-
centration of amiodarone and desethylamiodarone never reached toxic level.5 
One way to overcome the use of some specified excipients may be to find 
novel excipients with better safety profile. However, for excipient suppliers 
developing a novel excipient is not very attractive because of the long develop-
ment times (from polymer class selection to the launch to commercial sales ~ 12 
years), high costs (~ $5–10 million) and risk of failure (54% probability of 
success).179 Also, pharma companies are often reluctant to use novel excipients.180 
A novel excipient needs to be toxicologically tested similarly to a new API.166,173 
This requires full evaluation – acute toxicity, subchronical, chronical, genotoxi-
city and reproductive toxicity studies, and ADME – which would be enormously 
expensive.46,181 Despite that, it must be realized that safety issues may only 
become apparent when the product is used on a larger scale. Therefore, the added 
value of the novel excipient in a specific paediatric medicinal product must be 
well balanced against the use of other excipients with an established safety 
profile, other dosage forms or other routes of administration.32 
The most attractive way to reduce the exposure to problematic excipients may 
be to use medicines available on the market which do not contain harmful ex-
cipients instead of those with given excipients. As stated in the WHO report, the 
frequency and severity of ADRs varies among countries not only because of 
factors such as the spectrum of disease, comorbidities, and different genetic 
composition but also owing to variations in medicine production, pharma-
ceutical quality, composition (excipients) of locally-produced pharmaceutical 
products, and differences in medicine use.112 As was shown by Brion et al., for 
75% of products prepared extemporaneously in one country there are suitable 
licensed alternatives available in other countries.182 
Two animal studies have compared the “classic” parenteral amiodarone 
formulation containing polysorbate 80 and benzyl alcohol with the aqueous 
formulation, free of these excipients. It was concluded that aqueous formulation 
is a safer alternative to “classic” amiodarone due to the lack of hypotensive and 
cardiotoxic effects related to the excipients in the standard product.183,184 
According to the study in humans by Gallik et al. aqueous amiodarone 
possesses PD effects that have been attributed to amiodarone, whereas it lacks 
the hypotensive effect of the standard intravenous amiodarone formulation.185 
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van Riet-Nales et al. identified in Dutch medicines database 3542 drug 
products authorized for one or more paediatric age groups. Of all oral liquid 
products 52% (208 out of 400) contained at least one excipient of concern; for 
22% an alternative liquid was available with the same API but not the given 
excipients.186 However, this study was looking at paediatric products in general 
and within one country. From neonatal point of view, it means that the 
availability of EOI-free products for substitution is probably lower as different 
products may not be interchangeable when needed for a specific age category.186 
Contrariwise, these results give a hint that product substitution is possible as a 
matter of principle. 
 
 
2.7 Summary of literature 
Besides the desired API medicines also contain pharmaceutical excipients that are 
intended to improve quality and patient acceptability of medicines. Most drug 
products cannot be made without the use of excipients. Although excipients 
should be pharmacologically inactive, they may indeed cause significant adverse 
effects or even death, particularly in neonates. Here, the different physiology and 
metabolism/ elimination capacity of neonates compared to adults and older children 
as well as into-group variations in different GA groups should be considered. 
Some excipients, i.e. parabens, propylene glycol, polysorbate 80, benzoates, 
benzyl alcohol, ethanol, saccharin sodium, sorbitol, and benzalkonium chloride 
have received considerable attention due to the possible adverse effects, parti-
cularly in neonates. Risks have been emphasized in several publications and 
recognized by the regulatory agencies. Still, there are very little systematic data 
about excipient exposure which is a cornerstone for a safety assessment. Only a 
few studies have looked at excipients exposure in children including neonates, 
most limited to a single country or small number of NICUs or of variable 
methodology. Europe-wide picture of excipients use in neonates is still missing. 
Moreover, there is a lack of information regarding the preferable/ optimal study 
methodology that should be used in the assessment of excipients exposure. We 
are not aware of any head to head comparison of different methods and thus the 
question how to navigate between different methods in excipient exposure 
research remains unanswered. 
Preventing the administration of potentially harmful excipients to neonates is 
complex. Neonates are routinely given medicines with no specific paediatric 
information and therefore age-appropriate formulations may, among other things, 
solve some excipient’s issues. Also, not all formulations with similar indications 
and APIs unconditionally contain the same excipients. The only study looking 
at product substitution as the opportunity to reduce exposure to EOI among pae-
diatric medicines was performed within one country and found safer alternative 
products for one-fifth of oral liquid products with potentially harmful exci-
pients.186 To our best knowledge there are no studies on a European scale looking 
at substitution possibilities in neonates.  
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3. AIMS OF THE RESEARCH 
The general aim of this thesis was to access the Europe-wide scale of neonatal 
excipient exposure with the emphasis to EOIs and to explore the opportunity for 
reduction of exposure to EOI through product substitution. 
 
The research had the following specific objectives: 
1. To compare two different study designs in medicine/ excipient exposure 
assessment to identify the impact of study design on obtained results and 
enable implementation of optimal study designs in relation to research 
question in future studies 
2. To compose a comprehensive list of medicines/ excipients used in European 
NICUs to identify the scale of the problem with overall number of different 
products used in neonates and proportion of products containing EOI 
3. To describe individual EOI administration to European neonates and identify 
factors associated with exposure to EOI to detect the highest risk situations 
and subpopulations 
4. To identify regional and unit-wide variations in neonatal exposure to EOI in 
European NICUs 
5. To determine opportunities for product substitution among those available 
on the European market in order to reduce the administration of EOI on 
product and individual level 
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4. MATERIALS AND METHODS 
This thesis is based on the two multicentre observational cross-sectional studies 
of routine clinical practice conducted in European NICUs as part of a European 
Study of Neonatal Exposure to Excipients (ESNEE) as presented in Table 10. 
 
Table 10. Description of studies and analyses of the thesis 
Study 
characteristics 
Timing Population/ 
prescriptions 
Primary aim Publication 
Service 
evaluation 
survey 
30.05.2011 – 
30.09.2011 
115 NICUs from 
20 countries 
To describe general 
exposure to EOI 
To explore 
opportunities for 
product substitution 
III 
Point 
prevalence 
study 
01.01.2012 – 
30.06.2012 
726 newborns 
from 89 NICUs 
from 21 
countries 
To describe 
administration of EOI 
and identify risk 
factors for exposure 
II 
Comparative 
methodology 
study 
Analysis of 
the SES vs. 
PPS 
APIs used in 
more than one 
unit in the SES 
To compare the effect 
of two cross-sectional 
study designs on 
estimates of 
medicines/ excipient 
use 
I 
API, active pharmaceutical ingredient; EOI, excipients of interest; NICU, neonatal intensive care 
unit; SES, service evaluation survey; PPS, point prevalence study 
 
 
4.1 Ethics 
All studies were conducted in compliance with the Guidelines of Good Clinical 
Practice (GCP)187 and the Declaration of Helsinki.188 The SES did not collect 
any personal data and so did not require ethics committee approval. For parti-
cipation in the PPS, Ethics Committee approval was obtained in compliance 
with the respective national guidelines (list available as supplementary material 
to Metsvaht et al.189). No consent for individual patients was sought, as all data 
were collected in routine clinical practice and anonymised before leaving study 
sites. 
 
 
4.2 Study design and data collection 
We invited to participate all 27 EU countries plus Iceland, Norway, Switzerland, 
and Serbia. A network of national contact persons (Lead Contacts) was built by 
the ESNEE consortium.190 Search for national Lead Contacts was carried out 
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through national professional/ scientific societies of neonatology, paediatrics 
and/ or perinatology as well as through personal contacts of the ESNEE con-
sortium members or other FP-7-funded consortia (NeoMero, TINN).191,192 
 
 
Sample size calculation 
In the SES study, the Lead Contacts were asked to recruit as many hospitals and 
units providing neonatal care in the country as possible and no formal sample 
size calculation was made. 
In the PPS, sample size estimation was intended to be based on cluster 
sampling analysis stratified by country, assuming conservatively a 15% neo-
natal admission rate of all live births21,193–195 and a response rate of 50–70% of 
invited units as described in previous neonatal surveys.196–199 Based on the 
Eurostat Nomenclature of territorial units for statistics (NUTS) (or equivalent if 
NUTS classification is not available for the country) regional distribution of the 
population and reported nation-wide birth rates, the number of potentially 
available neonatal admissions was calculated and the representative sample size 
estimated for each country and region.200 A complete list of institutions involved 
in neonatal care was to be created for each randomly chosen NUTS2 region 
with subsequent involvement of all units to cover a whole region with pro-
portional representation of different unit levels. As a full list of neonatal units 
was not available and the response rate in the SES did suggest insufficient 
recruitment, similarly to the SES, all contacts provided by Lead Contacts were 
invited to participate in the PPS. 
 
 
Participating units 
All general neonatal, intermediate and neonatal intensive care, as well as mixed 
paediatric and neonatal intensive care units with more than 50% of admissions 
consisting of neonates, were eligible. Units were stratified according to the level 
of care as follows: level 1 providing neonatal special care; level 2 providing high 
dependency care, short-term intensive care and low birth weight (< 2500 g.) care, 
and level 3 providing comprehensive intensive care including extremely low 
birth weight (< 1000 g.) infants.201,202 Units offering different levels of care 
were classified according to the highest level they provided. 
 
 
Data collection 
In both studies all eligible neonates (≤28 days of postnatal age) in the unit at 
8 a.m. on the study day(s) were included. Each participating unit was free to 
choose the most appropriate day(s) for data collection during a prespecified 
period – from May 30th to September 30th, 2011 in the SES, and one of three 
fixed two-week periods from January 1st to June 30th, 2012 in the PPS. 
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In the SES all medicines prescribed to neonates were recorded on pre-for-
mulated Excel spreadsheets over three consecutive days as detailed in Table 11. 
In the PPS data collection was performed in a pre-populated web-based data-
base within one day. Individual prescriptions and demographic data were re-
corded for all neonates receiving any prescriptions active on the study morning 
at 8 a.m as detailed in Table 11. 
In both studies, printable data collection forms were available as an alter-
native to electronic data insertion. 
 
Table 11. Data collected during the SES and PPS 
Hospital form (only PPS) Hospital name, population coverage, sub-type of 
hospitala, name/ email/ post address of the ESNEE 
administrator/ contact person, names of neonatal units, 
names/ emails of local investigators 
Department form (SES and 
PPS) 
Date of survey, name of department, type of 
department, annual neonatal admissions/ admissions 
<32 weeks of GA, number of neonates during survey, 
number of patients receiving any drug 
Neonatal demographic data 
(only PPS) 
Patient identifier, date of birth, gender, APGAR score, 
GA, birth/ current weight, organ failures 
Drug form (SES and PPS) Trade name, manufacturer, active pharmaceutical 
ingredient, strength, strength unit, dosage form, route of 
administration 
Prescription form (only PPS) Single dose/ times a day, start of treatment 
ateaching or non-teaching hospital 
GA, gestational age; SES, service evaluation survey; PPS, point prevalence study 
 
All prescriptions, including micronutrients, iron, vitamins, parenteral nutrition 
solutions, and topical agents were recorded. Blood products, glucose and 
electrolyte solutions, vaccines, nursery care topical agents, herbal medicines, 
and food including breast milk fortifiers were excluded. Extemporaneous/ 
compounded forms of medicines were not included in described analysis. 
In both studies, the data were pooled for analysis without any comment on 
treatment strategies of individual participating units. 
 
 
4.3 Data management 
SES data collection forms were checked for legibility with two rounds of queries 
regarding missing data. Each drug product was classified according to trade 
name (i.e. brand name), manufacturer, pharmaceutical dosage form, and strength 
of API. The list of medicines obtained in the SES was used to prepopulate 
choices in the PPS database. To minimize the risk of data entry errors all “newly 
appearing” drug products in the PPS were added to the database by the ESNEE 
team. 
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4.4 Identification of excipients 
Excipient content for each medicine was identified from the national SmPC 
which were first accessed through national medicines agencies and then through 
medicines agencies of other European countries if the drug product was not 
registered in the specified country. If needed, further searches from the 
homepages of manufacturers as well as from credible public databases (e.g. 
www.diagnosia.com), were performed. Finally, local hospital contacts were 
asked to provide information regarding excipient composition for medicines 
with no SmPC available. 
Due to the significant amount of synonyms used in SmPCs the list of 
identified excipients was reviewed for possible overlaps using non-proprietary-, 
trade-, and chemical names, and Chemical Abstracts Service (CAS) registry 
numbers. Excipients having different names but a same chemical base were 
consolidated, e.g. dibasic sodium phosphate includes anhydrous, dihydrate and 
dodecahydrate forms. 
For more detailed analyses only EOI we included as detailed in Table 4 and 
Table 5. An excipient was considered as EOI if it was known to be harmful in 
neonates. The priority list of EOI for investigation (Table 5), was agreed upon 
using surveys conducted by the UK and Estonian partners.15,190 Polysorbate 80 
was included in the priority list on the advice of EMA.190 
Finally, EOI were categorised in a non-exhaustive way into three groups 
based on main function: antimicrobial preservatives, i.e. parabens (propyl-, ethyl-, 
and methylparaben), benzoates (benzyl alcohol, benzoic acid, and sodium 
benzoate), and benzalkonium chloride; solvents and solubilising agents, i.e. 
propylene glycol, polysorbate 80, and ethanol; and sweetening agents, i.e. 
sorbitol and saccharin sodium. Although benzyl alcohol does not belong to 
benzoates chemically, in this study, it was included into benzoates group as a 
precursor of benzoic acid in humans. 
 
 
4.5 Data analysis 
Descriptive statistics were used as appropriate to describe the main features of 
collected data: 
- Characterisation of participating units 
o Number of units from each country 
o Proportion of annual live births and neonatal admissions covered by 
study units in participating countries 
o Prevalence of different levels of care and teaching hospitals 
- Consumption of medicines 
o Number of different formulations according to API, manufacturer, dosage 
form, route of administration, and strength of API 
o Comparison of estimated frequency of medicine use between the SES and 
PPS 
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- Demographic characteristics and prescription data of patients 
o Number/ proportion of neonates with at least one drug prescription 
o Number of prescriptions per neonate in relation to the GA in the PPS 
- The general extent of EOI administration 
o Number/ proportion of products/ prescriptions containing at least one or 
more EOI in relation to the route of administration and geographical 
region 
o Number/ proportion of neonates exposed to EOI 
 
Characteristics of a variable’s distribution are presented in tabular format and 
histograms; measures of central tendency (the mean, median) and variability 
(SD, IQR) were used where appropriate. To compare variables between each 
other and between the two study contingency tables were used to find odds 
ratios and confidence intervals. 
Logistic regression analyses were performed to find the effect of study design 
in medicine use assessment and identify factors associated with the administration 
of EOI. Analyses were performed with Stata Software (ver. 12.1). 
Product substitution analysis was performed with Microsoft® Excel 2013 
(ver. 15.0). Simple logistic regression was used to determine the reduction in 
the odds of neonatal exposure to EOI through substitution.203 
 
 
4.5.1 Exposure to EOI: extent and risk factors 
The PPS data were used to estimate the influence of covariates on the 
administration of each EOI. 
First, univariate logistic regression analysis was used to study the effect of 
potential covariates on the administration of each EOI (Table 13). 
Further, a three-step multivariable logistic regression analysis was applied. 
All covariates with p < 0.05 from the univariate analysis were fitted into mixed 
effects models (Table 13). Model 1 aimed to identify variables associated with 
EOI administration to individual neonates. East region and extremely preterm 
neonates were used as the reference. Model 2 aimed to describe the associations 
between the above-mentioned covariates and the presence of a particular 
excipient in each prescription. In addition to covariates explored in model 1, 
API was included to adjust for variations in EOI administration by API. APIs 
were classified according to the 1st level of Anatomical Therapeutic Chemical 
(ATC) classification; the 3rd level grouping was used for antibiotics. ATC 
group with the largest number of prescriptions with respective excipient was 
used as a reference. Finally, the route of administration was added into model 2 
(Model 3) to inform on formulation-related variance and to estimate the 
potential for product substitution. Topical prescriptions were excluded from the 
latter analysis due to small numbers of prescriptions. 
 
 
45 
Table 13. Statistical analyses in risk factor analysis 
Model Tested variables Outcome variable 
Univariate logistic 
regression analysis 
Geographical regiona
GA categoryb 
Hospital teaching status 
Level of carec 
Administration of a specified 
excipient to a neonate, yes/no 
Three-step multivariable 
logistical regression 
analysis 
  
Model 1 Geographical regiona
GA categoryb 
Level of carec 
Administration of a specified 
excipient to a neonate, yes/no 
Model 2 API in addition to Model 1 
variables 
Presence of a specified 
excipient in a prescription, 
yes/no Model 3 RofA in addition to Model 2 
API, active pharmaceutical ingredient; GA, gestational age; RofA, route of administration 
aNorthern, Southern, Western, and Eastern Europe according to the United Nations Statistics 
Department)204 
b<28 weeks, called extremely preterm; 28 to <32 weeks very preterm; 32 to <37 weeks late 
preterm, and >37 weeks term neonates205 
cLevel 1 with neonatal special care; level 2 with high dependency care, short-term intensive care, 
and low birth weight care, and level 3 with comprehensive intensive care for extremely low birth 
weight infants available201,202 
 
The likelihood ratio statistic for testing the null hypothesis of zero between-
group variance confirmed the need for the addition of department to the models 
as a random effect to adjust for between-department variance. 
 
 
4.5.2 Product substitution 
The substitution was defined as a replacement possibility of an EOI-containing 
product with an EOI-free counterpart; a list of products created in the SES and 
complemented with products reported only in the PPS was used. Only APIs 
used in ≥10% of units in the SES with at least one product containing EOI were 
included (paper III, Figure 1). Products considered as an alternative for 
substitution had to be free of any EOIs. 
Substitution analysis did not include topical medicines due to the limited 
number of products. Also, multivitamins were excluded as defining adequate 
substitution possibilities proved unfeasible due to high variability in the com-
position of the multiple products used. 
Opportunities for product substitution were evaluated in three stages 
(Figure 2). 
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The first stage was based on similarity of API and route of administration. In the 
second stage, dosage form was included to provide differentiation between liquid 
and solid forms of enteral medicines: “solution for injection”, “powder for re-
constitution”, and “solution for injection/ oral” were all considered equivalent 
forms for parenteral administration; “oral solution”, “oral drops”, “oral suspen-
sion”, “granules for reconstitution”, “powder for reconstitution”, “syrup”, “solu-
tion for injection/ oral”, and “emulsion” were considered equivalent forms for 
enteral administration. The third stage also included the strength of API to 
identify the extent of an “ideal” substitution available. Here we assumed that the 
strength of API in substituted product was optimal for the NICU where it had 
been used. 
Subsequently, PPS data were used to explore potential reduction of individual 
exposure to EOI when all product substitution possibilities based on the second 
stage criteria were applied. 
 
 
4.5.3 Effect of study methodology in medicine use assessment 
Primary endpoints of the comparative methodology analysis were to find the 
average probabilities of the units to use any given API in the SES versus PPS and 
thereby to identify the effect size of the study method. 
Secondary endpoints were to describe the implementation of each method 
and to explore the correlation between medicines’ exposure at unit and individual 
levels. 
Exploratory data analysis with ten most often used APIs was done to find 
potential confounders for further analysis. Population averaged Poisson reg-
ression model with robust standard errors206 was used (Table 14). The analysis 
included all units in both studies and was adjusted for department level, the 
status of teaching or non-teaching hospital, and European region; the p-values 
were corrected for multiple testing using Holm correction207. 
 
 
 
Figure 2. Criteria for substitution according to the stages of analysis 
Stage 1
•Medicines could be substituted with a product with the same active 
pharmaceutical ingredient and route of administration
Stage 2
•Stage 1 plus requirement of identical dosage form
Stage 3
•Stages 1 and 2, plus requirement of identical strength of the active 
pharmaceutical ingredient
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Table 14. Statistical analyses in comparative study 
Model Included APIs Tested variables 
Population averaged Poisson 
regression model with robust 
standard errors206 
10 most often used 
APIs 
Hospital teaching status 
Geographical regiona 
Level of careb 
Multilevel mixed effects 
logistic regression models with 
crossed random effects208 
APIs used in more 
than one unit in the 
SES 
Geographical regiona 
Level of careb 
Unit sizec
Frequency of used 
Duration of the prescriptione 
Polynomial regression model 
with square root 
transformation 
None 
API, active pharmaceutical ingredient; SES, service evaluation survey 
aNorthern, Southern, Western, and Eastern Europe according to the United Nations Statistics 
department204 
bLevel 1 with neonatal special care; level 2 with high dependency care, short-term intensive care 
and low birth weight care, and level 3 with comprehensive intensive care for extremely low birth 
weight infants available201,202 
cDescribed by number of annual admissions 
dDescribed by proportion of units using given API 
eDescribed by the average time from the start of prescription to the PPS study day 
 
Considering the data structure with repeated observations on both department 
and API level, to eliminate possible deficiencies in statistical power multilevel 
mixed effects logistic regression models with crossed random effects208 were 
used (Table 14) to identify the effect size of the study method. Since the sample 
of departments in the two studies was partly overlapping, department and API 
were added to the model as a random effect when comparing the average odds 
of using an API between the two study methods. The outcome variable was a 
binary indicator showing whether an API was used in a specific unit in a 
specific study. All models were adjusted for potential confounders identified in 
an initial analysis. 
As the assessment is likely to be affected by a number of additional para-
meters related to the use of a given drug, unit size, frequency of the use, and 
duration of the prescription were added into the analysis as covariates. 
As nonlinear relationship between the number of units using each API and 
the number of prescriptions for that API was suggested, a polynomial regression 
model with square root transformation was used to study given relationship. 
The analysis was based on the PPS data. 
The use of caffeine and morphine was reported differently in the two studies. 
UK units using “special” manufactured209 preparations, rather than extem-
poraneous formulations used in the rest of European countries, were over-rep-
resented in the PPS. Accordingly, these two APIs were excluded from the 
analysis. 
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5. RESULTS AND DISCUSSION 
“Supposing is good, but finding out is better.” (Mark Twain; 1835–1910) 
 
 
5.1 Participating units in the SES and PPS 
Altogether 20 and 21 countries (Figure 3) with 115 and 89 neonatal units joined 
the SES and PPS, respectively. The number of units per country varied from 
one to 20 (Figure 3). Data on drug use from Sweden were available only with 
respect to the whole country from a 4-day national study of drug consumption 
in 38 NICUs conducted previously in 2008; data by units were not available and 
thus could not be used in analysis of drug use frequency and variations, but drug 
list from this study was used in product substitution analysis. 
 
 
 
(a) 
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Figure 3. Number of units participating in the SES (a) and PPS (b) by country. Blue 
color indicates Northern, yellow Western, green Eastern, and red Southern European 
region according to the United Nations Statistics Department.204 Number of neonatal 
units participating from each country is shown in parentheses. 
In the SES a higher proportion of annual live births was covered compared to 
the PPS – 11% vs. 6% of 5,572,859 live births in invited countries in 2010, 
respectively; OR 1.89; 95% CI 1.87–1.89. Similarly, the proportion of annual 
admissions in participating units covered by the study was higher in the SES 
than the PPS (3% and 2% of 90,235 and 61,392 admissions, respectively; OR 
1.58; 95% CI 1.48–1.68). Regional distribution was similar in both studies 
(paper I, Table 1). No difference in the prevalence of different levels of care 
between the two studies was observed. The lower prevalence of teaching 
hospitals in the SES as compared to the PPS (OR 0.47; 95% CI 0.24–0.92) 
(paper I, Table 1) makes the speculative assumption that physicians from bigger 
hospitals are more keen to be involved in more detailed and individualised 
approach. Prepopulation of a major part of the PPS database with no doubt 
makes it more attractive for researchers as well. 
 
(b) 
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We have recruited so far one of the largest international cohorts of neonatal 
units from 21 European countries. Of note, the study did not involve some large 
European countries such as Germany. Altogether, 71% of invited countries 
participated. The number of units (by country coverage of live births) varied 
from 0.8% to 100%. 
Due to the aim of attracting as many units as possible, hospitals were not 
randomly selected, that probably caused overrepresentation of tertiary or 
teaching hospitals (61% in the SES, 77% in the PPS compared to less than 10% 
according to available national hospital statistics210). Nevertheless, data on the 
distribution of the levels of neonatal care allowed appropriate adjustments and 
both the SES and PPS have achieved representative sample size with a margin 
of error being 1.73% and 2.63%, respectively (CI 95%; response distribution 
50%). However, it would be valid under the condition of randomisation that 
remained unfeasible in our studies due to the lack of comprehensive list of 
neonatal units as well as relatively modest response rate. Still, current retro-
spective calculation of study power gives a notion of good coverage of the 
studied population in the SES and PPS. 
 
5.2 Medicines consumption in European NICUs 
In the SES 313 APIs representing 1065 products from 332 manufacturers were 
registered. Parenteral formulations predominated with 616 (58%) products, 
followed by enteral and topical formulations with 325 (31%) and 124 (12%) 
products, respectively (Table 15). 
In the PPS 1382 neonates received 2608 prescriptions for 624 products 
containing 280 APIs (Table 15). Excluding neonates > 28 days of age, without 
any drug prescription during the study day, and those receiving only prescrip-
tions with unavailable excipient content data, the further analysis included 726 
neonates, 2199 prescriptions, 562 products, and 246 APIs. Demographic 
characteristics of patients and prescription data are shown in paper II, Table 2. 
Slightly lower prevalence of enteral and higher prevalence of topical formu-
lations was noted in the SES compared to the PPS with no difference in 
parenteral medicines use (paper I, Table 2). 
Table 15. Drug use variability 
 SES PPS 
No of prescriptions during the study period NA 2608 
Median (IQR) No of prescriptions per neonate NA 2 (1;4) 
No of APIs prescribed* 313 280 
No of trade names (by name, manufacturer, pharmaceutical 
dosage form, and strength) 
1065 624 
No of manufacturers 332 235 
*all components in multicomponent drugs are counted separately 
API, active pharmaceutical ingredient; IQR, interquartile range; NA, not applicable; PPS, point 
prevalence study; SES, service evaluation survey 
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Thus, the longer study period (period prevalence in the SES vs. point prevalence 
in the PPS) and larger number of participating units in the SES expectedly 
resulted in a more comprehensive list of APIs as well as drug products. 
In the PPS the number of prescriptions per neonate was inversely related to 
GA (Spearman’s rank correlation coefficient –0.3949; p<0.0005), the average 
(SD) count per neonate being 4.53 (2.33); 3.95 (2.59); 2.68 (1.91), and 2.31 
(1.93) in the extremely preterm, very preterm, late preterm, and term neonates, 
respectively. Higher drug utilization rates in preterm neonates as compared to 
term neonates have been described in previous studies. 24,131 That in combi-
nation with organ immaturity is putting preterm neonates at a higher risk of 
ADRs, including those related to excipients. For example, potentially toxic 
cumulative doses of benzyl alcohol and propylene glycol received by neonates 
during routine treatment were reported by Shehab et al.,134 where neonates 
received up to four medicines containing benzyl alcohol (midazolam, 
phenobarbital, pancuronium, dexamethasone) and up to three medicines with 
propylene glycol (lorazepam, phenobarbital, digoxin). 
The list of ten most often used medicines included nine APIs presented in 
both studies and also furosemide in the SES and caffeine in the PPS (Table 16). 
Not surprisingly, this list contains four antibacterials for systemic use. 
Antibacterials were found to be the most commonly prescribed medicines in 
NICUs almost in all studies.20,24,131,136 
 
Table 16. Frequency of use and variety of drug products for ten most frequently 
prescribed APIs 
ATC class (2nd level) Active substance % of units using No of products 
SES PPS SES PPS 
Antibacterials for systemic 
use (J01) 
gentamicin 74.1 51.7 26 21 
ampicillin 60.2 40.5 20 22 
vancomycin 40.7 28.1 21 20 
benzylpenicillin 32.4 26.9 7 11 
Antihemorrhagics (B02) phytomenadione 73.2 31.5 11 11 
Antianemic preparations 
(B03) 
iron 57.4 37.1 27 18 
Blood substitutes and 
perfusion solutions (B05) 
amino acids 56.5 30.3 11 5 
lipids 44.4 25.8 7 6 
Diuretics (C03) furosemide 39.8 14.6 20 9 
Vitamins (A11) colecalciferol 37.9 41.6 16 22 
Psychoanaleptics (N06) caffeine 24.1 34.8 17 19 
API, active pharmaceutical ingredient; ATC, anatomical therapeutical class; PPS, point 
prevalence study; SES, service evaluation survey 
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Among these commonly prescribed APIs EOI were previously reported in 
gentamicin, caffeine, iron, phytomenadione, and furosemide.14–16,135,211 
Great variation in products was observed for frequently used APIs in both 
studies (Table 16, Figure 4). 
 
Three most frequently used formulations usually covered over 50% of units in 
both studies (mean%; SD: 64; 18 and 60; 20 in the SES and PPS, respectively). 
This means that in the case of the presence of EOI in these formulations 
substitution of a relatively small number of products may noticeably decrease 
neonatal exposure to these excipients. 
 
 
 
 
 
 
Figure 4. Variation of drug products for five most commonly used active ingredients 
(API) with proportion of units using each specified product* 
PPS, point prevalence study; SES, service evaluation survey 
*Each color indicates a single product. Similar color does not indicate identical products neither 
in the SES and PPS nor for different APIs 
0% 20% 40% 60% 80% 100%
amino acid solution PPS
amino acid solution SES
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5.3 Excipients in prescribed medicines –  
the scope of exposure 
5.3.1 Describing the content of excipients in medicines 
SmPCs were attainable for 927 (87%) of the 1065 reported medicines; for 77 
(7%) products excipient data were obtained from queries. Thus, information on 
excipient composition was available for 1004 (94% of 1065) products. Usually, 
only qualitative data were presented, with quantitative excipient data available 
from public sources for only 6% of medicines. After unification of synonyms 
according to the European Pharmacopeia and integration of excipients with 
identical chemical base into one, overall 396 different excipients were 
identified. Among products without any excipients in the powder form prior 
administration (n=117) almost all were for parenteral use (n=111) with only six 
enteral formulations (Figure 5). 
 
 
5.3.2 The presence of EOI in medicines prescribed to neonates 
Altogether 305 (30%) products contained at least one and 132 (13%) two and 
more EOIs (Figure 6). The median number of EOI per formulation was one (IQR 
1; 2) with a maximum number of six (excipients from one group were counted 
once, e.g. methyl- and propylparabens). A higher proportion of products with EOI 
was observed in Northern NICUs compared with Western units (OR 1.83; 95% 
CI 1.24–2.68) with no differences between other European regions. 
 
 
Figure 5. Proportion of products containing at least one excipient by route of 
administration in the SES 
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Of 2199 prescriptions and 562 products administered to 726 neonates in the 
PPS, excipient composition was available for 530 (94%) products with 2095 
(95%) prescriptions. 
54 
 
Figure 6. Number of products with one or more EOI in the SES 
EOI, excipient of interest; SES, service evaluation survey 
 
At least one EOI was found more frequently in enteral and topical compared to 
parenteral medicines (OR 8.4; 95% CI 6.1–11.7 and 6.2; 4.02–9.5, respectively) 
but no difference was found between enteral and topical formulations (OR 1.4; 
95% CI 0.9–2.1) (Figure 7). 
 
 
Figure 7. Proportion of products containing at least one EOI by route of administration 
in the SES 
EOI, excipient of interest; SES, service evaluation survey 
 
Similar tendency was found for every single EOI with the exception for 
benzalkonium chloride present exclusively in topical formulations (Figure 8). 
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The presence of sweeteners in almost all enteral formulations is logical; taste-
masking is needed to increase compliance with therapy among children.149 As 
the most common type of paediatric products are oral liquid solubilized multiple-
use formulations,149 the dose and volume may be limited by the solubility of 
API requiring the addition of cosolvent and surfactant excipients; additionally, 
physical, chemical, and microbiological stability must be assured with buffering 
agents, antioxidants, and antimicrobial preservatives.212 The use of potentially 
harmful solvents can be avoided e.g. if an API is water-soluble and chemically 
stable in an aqueous formulation.149 Additionally, solvent e.g. propylene glycol 
may be included in formulation to dissolve preservatives.213 
Regarding the presence of EOI according to the route of administration our 
data are partly similar to the data from the Netherlands, where 52% of oral 
liquid formulations and 7% of all parenteral medicines in the country authorized 
for one or more paediatric age groups contained EOI.186 The lower proportion of 
products with EOI compared to our study is likely explained by the methodo-
logical differences; polysorbate 80, saccharin sodium, and sorbitol were not 
included in the EOI list. In contrast, in Estonian15 and Spanish150 studies, 
looking at medicines prescribed to neonates within a single country and a single 
hospital, 62% and 32% of parenteral, and 100% and 62% of enteral products 
contained EOI, respectively. However, in our and the Dutch studies only 
“known to be harmful” excipients were taken into the analysis, while in 
Estonian and Spanish studies a very conservative approach was taken and the 
excipients were classified into the “potentially harmful” category even if only 
some data on human toxicity had been published. Interestingly, Garcia-Palop et 
 
Figure 8. EOI in prescribed medicines by route of administration in the SES 
Benzoates include benzyl alcohol, sodium benzoate, and benzoic acid; parabens include propyl- 
and methylparabens; EOI, excipient of interest; SES, service evaluation survey 
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al. did not include polysorbate 80 known for the “E-Ferol syndrome” in the list 
of harmful excipients.150 
 
 
5.3.3 Individual exposure to EOI 
The presence of EOI in products by route of administration in the PPS was 
similar to that observed in the SES – enteral and topical formulations contained 
EOI more frequently than parenteral (OR 6.3; 95% CI 4.1–9.7 and OR 10; 95% 
CI 4.4–22.9, respectively). Out of 638 prescriptions with EOI, 328 (51%), 276 
(43%) and 34 (5%) were administered enterally, parenterally, and topically, 
respectively. In 452 (22% of all and 71% of those with EOI) prescriptions and 
89 (17% and 63%) products, more than one EOI was involved. Distribution of 
EOI by product, prescription, and neonate is shown in Table 17. 
 
Table 17. Count and proportion of products and prescriptions containing each EOI and 
number of neonates exposed 
EOI No. (%) of 
products 
N = (530)a 
No. (%) of 
prescriptions 
(N = 2095)a 
No. (%) of 
neonates 
(N = 726) 
Solvents and solubilising agents    
Polysorbate 80  18 (3) 139 (7) 138 (19) 
Propylene glycol 26 (5) 129 (6) 120 (17) 
Ethanol 20 (4) 47 (2) 47 (7) 
Antimicrobials    
Parabensb 71 (12) 397 (19) 313 (43) 
Benzoatesc 27 (5) 93 (4) 82 (11) 
Benzalkonium chloride 10 (2) 27 (1) 26 (4) 
Sweeteners    
Saccharin sodium 31 (6) 104 (5) 90 (12) 
Sorbitol 24 (5) 64 (3) 57 (8) 
At least one EOI 142 (27) 638 (31) 456 (63) 
anumber of products and prescriptions with available excipient content data 
bparabens include propyl-, ethyl-, and methylparabens; 
cbenzoates include benzyl alcohol, benzoic acid, and sodium benzoate 
EOI, excipient of interest 
 
More than a half of neonates were exposed to at least one EOI. Furthermore, in 
some cases simultaneous administration of up to nine EOI from six different 
medicines was observed; 9% (n = 39) received five and more EOI during study 
day. Our results suggest poor compliance with existing administrative require-
ments/ recommendations. While European Commission guidelines pursuant to 
Article 65 of Directive 2001/83/EC contain warning statements relating to the 
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presence of certain excipients in medicinal products (e.g., parabens, topical pro-
pylene glycol, sorbitol, benzalkonium chloride, benzyl alcohol, and benzoates)98 
and the EMA Reflection paper has cautioned about the use of benzoates in 
neonates,10 in this study parabens, propylene glycol, and benzoates (including 
benzyl alcohol) were administered to 43%, 17%, and 11% of neonates, respec-
tively (Table 17). Parabens were the most and benzalkonium chloride least fre-
quently administered EOI. The largest proportion of parabens use was asso-
ciated with parenteral gentamicin for which also paraben-free formulations were 
available. Similar results were shown by Lass et al. – paraben-containing paren-
teral gentamicin was given to 57% of treated neonates being the main source of 
this excipient.214 
It is noteworthy, that in the context of such extensive exposure of neonates 
to EOI, “only” 27% of products contained given excipients. This suggests that 
the major part of exposure to EOI are from most commonly used products, 
meaning that significant reduction in administration of EOI to neonates may be 
achieved through substitution or reformulation of a relatively small number of 
products. 
 
 
5.4 Covariates associated with EOI administration 
In univariate logistic regression analysis by EOI route of administration, GA 
category, geographical region, and department level were identified as signi-
ficant covariates of administration (data not shown). Variations of exposure in 
relation to GA and geographical region on the example of parabens and ethanol 
are shown in Figure 9. Compared to East, parabens were administered more 
frequently in all other regions, and ethanol in North and West Europe (p < 0.05). 
Term neonates were exposed more frequently to parabens, and term and late 
preterm newborns to ethanol compared to extremely preterms (p < 0.05). 
The effects of significant covariates from univariate analysis on EOI 
administration in multivariate logistic regression analysis are shown in Table 18 
and Table 19. 
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5.4.1 EOI administration by geographical region 
Region was a determinant of EOI administration regardless of excipient class. 
Significant variations were observed in the use of parabens, polysorbate 80, pro-
pylene glycol, and saccharin sodium (Table 18). Adjusting for ATC group and 
route of administration did not change the regional effect (Table 19). This sug-
gests that medicines of the same ATC group and same route of administration 
but various EOI content are used in different regions. Hence, EOI-free 
formulations are feasible and available on the European market and therefore 
some EOI administration could be avoidable if different products containing the 
same API were used. 
Regional differences in parabens administration were driven by choice of 
vitamin preparations (118/477 containing parabens), responsible for 118/397 
paraben-containing prescriptions. The proportion of vitamin prescriptions con-
taining parabens varied from 3–24% (3/98 in East and 33/137 in West) to a 
third (56/164 in North and 26/78 in South). 
Domperidone, prescribed in North and South, and carnitine, prescribed in 
West, were responsible for 30% of prescriptions containing saccharin sodium 
but were not used in the East. No reasons could be identified for variations in 
polysorbate 80 and propylene glycol administration. 
 
 
5.4.2 EOI administration by gestational age 
In univariate analysis no association between GA and administration of at least 
one EOI was found; the median (IQR) number of EOI per neonate of 1 (0; 2) 
was identical for all GA bands. However, due to the decreasing number of 
prescriptions per neonate with increasing GA, the proportion of prescriptions 
containing at least one EOI was greater in term and late preterm compared to 
extremely preterm neonates (OR 1.9; 95% CI 1.4 to 2.6 and OR 1.5; 95% CI 1.1 
to 2, respectively). The extent of EOI administration by GA band is presented in 
paper II, Figure 2. 
 
In multivariate analysis, in model 1 term GA was associated with a lower 
likelihood of parabens, ethanol, and benzoates administration; late preterm with 
a lower likelihood of ethanol, and very preterm GA with a higher likelihood of 
saccharin sodium administration compared to extremely preterm GA (Table 
18). When adjusting for ATC group (model 2), these associations were no 
longer significant except for saccharin sodium (OR 2.8; 95% CI 1.1–7.3). Thus, 
variations in the administration of parabens, benzoates, and ethanol were 
probably driven by variations in API distribution rather than by use of different 
drug formulations (routes of administration). After adding a route of adminis-
ration to the model, the association was not significant for saccharin sodium 
anymore. 
In contrast to model 1, in model 2 late preterm infants were more likely to 
receive polysorbate 80 (OR 4.5; 95% CI 1.6–12.2) and term newborns 
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polysorbate 80 (OR 13.8; 95% CI 4.9–39.2), propylene glycol (OR 8.4; 95% CI 
3.2–21.8), saccharin sodium (OR 3.2; 95% CI 1.1–9.3) and sorbitol (OR 8.9; 
95% CI 2.4–33.3) compared to extremely premature neonates. Except for pro-
pylene glycol, these excipients are found predominantly in enteral formulations 
(Figure 8). After adjusting for the route of administration, these associations 
remained significant for all EOI mentioned above except for saccharin sodium 
(Table 19). Together with major regional variation, this may reflect deliberate 
choices due to awareness of possible hazards considered more relevant in 
extremely preterm than term infants. 
 
 
5.4.3 EOI administration by route of administration 
Parenteral route was associated with a lower likelihood of administration for 
five studied EOI (parabens, polysorbate 80, benzoates, propylene glycol, and 
sorbitol) regardless of functional group (Table 19). Saccharin sodium, ethanol, 
and benzalkonium chloride were not included in this analysis due to small 
sample sizes and the predominance of a single route of administration – 
saccharin sodium was found exclusively and ethanol in 79% (37/47) of 
prescriptions in enteral formulations; benzalkonium chloride in 85% (23/27) of 
prescriptions in topical formulations. 
The risks of ADR to the patient are proportional to the route of administration, 
approximately increasing in the following sequence: topical, oral and rectal, 
pulmonary/ inhalation, parenteral, ophthalmic, and preparations intended for use 
in open wounds.166 The route of administration is also critical to defining the 
requirements for the excipient. It is accepted that oral route is the most preferred 
and appropriate route of administration in paediatric patients.33 This may not 
always be a “gold standard” due to the extensive variability in children with 
special needs for drug formulations in different paediatric age groups and parti-
cularly neonates.215 In case of oral medicines neonates should be given liquid 
formulations that could be easily swallowed. However, special attention has to 
be paid to the in-use quality of multidose preparations, regarding both microbial 
and chemical stability.33 As showed by us and by others, EOI are often required 
in liquid products as solvents, antimicrobial preservatives, and/ or taste-
masking/ sweeteners.186,216 
 
 
5.4.4 EOI administration by ATC group 
In the prescription-based multivariate analysis (Model 3), ATC group was a 
significant determinant of administration for all EOI except polysorbate 80 
(Table 19). ATC groups with highest proportion and number of prescriptions 
containing each EOI are shown in Table 20. 
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Table 20. ATC groups with highest proportion and number of prescriptions containing 
EOI 
EOI ATC group with highest 
proportion of prescriptions
ATC group with highest 
number of prescriptions 
Solvents and solubilising 
agents 
  
Propylene glycol B (phytomenadione, iron) B (phytomenadione, iron) 
Ethanol G (dinoprostone) A (mainly enteral vitamins) 
Antimicrobials   
Parabensa J01G (gentamicin) A (mainly enteral vitamins) 
Benzoatesb J01F (lincomycin, 
clindamycin) 
A (mainly enteral vitamins) 
Benzalkonium chloride S (tobramycin, 
chloramphenicol, 
ciprofloxacin – all topical) 
S (tobramycin, 
chloramphenicol, 
ciprofloxacin – all topical) 
Sweeteners   
Sorbitol B (phytomenadione, iron) A (mainly enteral vitamins) 
Saccharin sodium A (mainly enteral vitamins) A (mainly enteral vitamins) 
aparabens include propyl-, ethyl-, and methylparabens 
bbenzoates include benzyl alcohol, benzoic acid, and sodium benzoate 
ATC, anatomical therapeutic chemical classification; EOI, excipient of interest 
 
Thus, the main source of parabens, benzoates, ethanol, sorbitol, and saccharin 
sodium are enteral multivitamins. Practitioners should pay special attention to 
prescribing vitamins. Enteral multivitamin products were commonly prescribed 
in our study with 6% (n = 133) of all prescriptions; 81% (n = 108) contained at 
least one EOI. Similar results were reported from a Brazilian NICU with oral 
multivitamins making up 7% of all prescriptions.135 
Medicines from ATC groups J01C (mainly ampicillin, benzylpenicillin), 
J01D (mainly cefotaxime, ceftazidime, meropenem), J01E (trimethoprim), 
J01M (ciprofloxacin), J01X (mainly metronidazole, teicoplanin, vancomycin), 
L (filgrastim), and M (pancuronium) did not contain any EOI. 
 
 
5.5 Substitution of EOI containing medicines  
with EOI-free counterparts 
Overall, 53 APIs were used in more than 10% of units. These APIs were 
administered through 564 products (53% of all products registered in the SES). 
Excluding topical medicines, multivitamins and APIs with no EOI, substitution 
analysis included 25 APIs in 318 products (paper III, Figure 1). 
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Substitution opportunities with the list of countries in which EOI-free products 
were available are presented in paper III, Table I for parenteral and Table II for 
enteral products. Opportunity for substitution was available in several countries. 
For example, enteral colecalciferol products containing propylene glycol, 
ethanol, parabens, and benzyl alcohol could be substituted with six EOI-free 
products available in ten countries; for parenteral gentamicin with parabens 
there are EOI-free alternatives in use in four countries. 
A major part of the reduction in number of products with EOI can be 
achieved by substitution of parenteral medicines – a greater proportion of 
parenteral products could be substituted compared to enteral medicines in both 
second stage (87% vs. 54%; OR 5.5; 95% CI 2.2–13.5) and third stage (64% vs. 
14%; OR 10.4; 95% CI 4.5–24). However, even for enteral medicines, in the 
second stage substitution was possible for 54% (46/85) of products. Switching 
to parenteral administration would allow replacing an additional 21 of 39 
enteral products (paper III, Table II). 
The first stage of substitution analysis provides an estimate of how many 
excipients are required for the stability of the API – APIs not having any EOI-free 
1. Substitution to reduce the number of products containing EOI 
 
At least one EOI was found in 137 out of 318 (43%) products, 85 of these were 
enteral formulations. 
When applying the first, second, and third stage criteria, the number of EOI 
containing products could be reduced by 88%, 66%, and 31%, respectively 
(Figure 10). 
 
 
Figure 10. Product substitution possibilitiesa according to criteria of three stages 
apresented as number of products; EOI, excipients of interest; Stage 1 – similar active 
pharmaceutical ingredient and route of administration; Stage 2 – stage 1 + similar dosage form; 
Stage 3 – stage 2 + similar strength of active pharmaceutical ingredient 
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alternatives available are most likely to require one or more of them for 
manufacturing purposes and the use of product(s) with EOI is justified. For 
parenterally administered medicines from 12 APIs EOI-free products were 
available for all but alprostadil (paper III, Figure 3). For enteral medicines, from 
17 APIs no substitution possibility was available for dexamethasone, dom-
peridone, fluconazole, ibuprofen, metronidazole, nystatin, paracetamol, pheno-
barbital, and ranitidine. Parenteral EOI-free formulations are available for all 
above-mentioned APIs except for nystatin and domperidone (paper III, Table II). 
The second stage provided discrimination between solid and liquid enteral 
formulations. For example, for nystatin an EOI-free tablet was available but 
should not be considered an adequate substitution possibility. Safe adminis-
tration of tablets to neonates is at least questionable if not impossible.32 
The third stage is important in neonatal practice because of possible limits 
on fluid administration but also dosing accuracy particularly in parenteral 
medicines. 
In a recent study conducted by Garcia-Palop et al. in a university hospital in 
Spain, the authors showed, that in comparison with ADI estimated for adults, 
neonates receiving parenteral diazepam, sodium heparin, gamma globulin, and 
naloxone were exposed to higher amounts of propylene glycol, benzyl alcohol, 
sorbitol, and MPB, respectively.150 Should be emphasized that for propylene 
glycol ADI for adults is 500 times greater than for neonates (500 vs 
1 mg/kg/day).66,107 According to our data, EOI-free products for all these APIs 
are available on the European market. 
 
 
2. Substitution to reduce the number of neonates exposed to EOI 
 
The analysis of potential product substitution for each neonate included 22 of 
the 25 APIs used in the analysis of products with 776 prescriptions (paper III, 
Figure 1). A half of these prescriptions (n = 372) contained EOI. Further results 
are presented in relation to all prescriptions (638/ 2095 with EOI) and neonates 
(456/ 726 exposed to EOI) from the PPS to indicate the overall benefit from the 
substitution of only the most commonly used medicines. After all available 
product substitutions of the 22 studied APIs the overall number of prescriptions 
with EOI in the PPS would be reduced by 50% (from 638 to 317; 95% CI 46–
54%; paper III, Table 3) and the number of exposed neonates by 44% (from 456 
to 257; 95% CI 39–48%; Figure 11). 
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After potential product substitution, the odds of neonatal exposure were signi-
ficantly lower for all EOI except for ethanol, saccharin sodium, and sorbitol 
(Figure 11; paper III, Figure 4). The availability of EOI-free products may be 
related to the role of the excipient in a formulation. For example, avoiding 
solvents like ethanol may be more difficult in the manufacturing process than 
antimicrobial preservatives like parabens in single-use parenteral products.32 
The situation is more complex for enteral products where multi-dose liquid 
formulations are frequently used and excipients are also needed to improve 
palatability and consistency (e.g. saccharin sodium and sorbitol).32 
Additionally, possible cumulative risks associated with exposure to EOI 
from multiple sources14,86,107,134 can be reduced by product substitution. Among 
257 neonates still exposed to at least one EOI after product substitution, 70 
neonates would benefit from being exposed to a lower number of EOI. 
Probably, overall cumulative gain from product substitution may be even 
greater. Iron, colecalciferol, and folic acid were prescribed in more than 10% of 
units. These products may contain all but one (benzalkonium chloride) EOI. 
Importantly, these liquid medications are commonly prescribed to preterm 
neonates for 3–6 months forming a “background” level of excipient exposure. 
We have shown that for all these drugs there are EOI-free products available on 
the European market. 
 
 
Figure 11. The number of neonates exposed to each EOI before and after product 
substitution and proportion of neonates favored from substitutiona 
apresented as overall reduction of neonatal exposure through the substitution of most frequently 
used medicines according to second-stage criteria – identical active pharmaceutical ingredient, 
route of administration, and dosage form; percentages indicate proportion of neonates favored 
from substitution; *lower odds of neonatal exposure after substitution (p < 0.05) 
Parabens include propyl-, ethyl-, and methylparabens; benzoates include benzyl alcohol, benzoic 
acid, and sodium benzoate; EOI, excipient of interest 
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5.6 Impact of study methodology on assessment  
of medicines use 
The average comparative probability of the departments to use ten most 
common APIs within the study period as revealed by the two methods is shown 
in Table 20. 
 
Table 20. The average probability of departments to use one of ten most common API 
in the SES compared to the PPS* 
API RR (95% CI) p-value 
Gentamicin 1.45 (1.18–1.78) 0.002 
Ampicillin 1.38 (1.10–1.74) 0.02 
Vancomycin 1.59 (1.17–2.17) 0.015 
Benzylpenicillin 1.32 (0.93–1.86) 0.38 
Phytomenadione 2.39 (1.75––3.27) <0.0005 
Iron 1.71 (1.29–2.26) 0.001 
Amino acids 1.99 (1.45–2.72) <0.0005 
Lipids 1.89 (1.34–2.65) 0.001 
Furosemide 2.81 (1.64–4.83) 0.001 
Colecalciferol 1.05 (0.81–1.38) 0.705 
*adjusted for department level, status of teaching or non-teaching hospital, and European region 
API, active pharmaceutical ingredient; RR, risk ratio; PPS, point prevalence study; SES, service 
evaluation survey 
 
For eight out of ten most frequently used APIs the likelihood of being captured 
in the SES was higher compared to the PPS. Further analysis included 99 APIs 
used in more than one unit in the SES. Almost all APIs were more frequently 
used in the SES compared to the PPS, but the 95% CIs were overlapping for the 
majority (paper I, Figure 1). High correlation in the frequency of medicine use 
between the SES and PPS for APIs used in more than one unit in the SES is 
shown in Figure 12. 
The estimates in the frequency of medicine use in the PPS were systemati-
cally lower compared to the SES. However, knowing the relationship between 
the two an estimate for one can be extrapolated from the other. 
In multilevel mixed effects logistic regression models with crossed random 
effects adjusted for geographical region and unit level the average probability of 
the departments to use each of the most common API (n = 99) was higher in the 
SES compared to the PPS (OR 2.36; 95% CI 2.05–2.73; p < 0.0005). The 
frequency of use and average duration of prescription further increased the 
likelihood of being registered in favor of the SES by 1.01 times (95% CI 1.01–
1.02; p < 0.0005) and 1.02 times (95% CI 1.00–1.05; p = 0.047) per each 
additional percent in frequency and day in duration of prescription, respectively.  
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Figure 12. Correlation in the frequency of medicine use between the SES and PPS on 
unit level 
Trendline for 99 active pharmaceutical ingredients: y = 0.6019x – 0.0053; R2 = 0.8605 
PPS, point prevalence study; SES, service evaluation survey 
 
Size of the department did not influence the capture probability (OR 0.99; 95% 
CI 0.99–1.00; p = 0.652). Thus, simple data structure and longer study period 
used in the SES improved recruitment and the likelihood of capture of 
medicines consumption, giving a more comprehensive list of drug products. 
We have also shown high correlation (R2 = 0.93) between the number of units 
using each specified API and the number of prescriptions in the PPS (Figure 13). 
Thus, the less demanding unit level approach like SES should allow an 
indirect individual exposure assessment under the condition of limited 
resources. Nevertheless, such calculations should be applied with caution and to 
estimate the exposure only for the studied population as a whole. It has been 
shown previously and also by us that medicines utilization pattern in extreme 
prematurity is different from that near or at term.19,20,24,131 Therefore, in neonatal 
studies stratification by GA age allows a more meaningful risk assessment, 
especially when also considering the strong dependence of the maturity of 
metabolic pathways on the postmenstrual age of the newborn.7,85 
Against the background of rising safety concerns of neonatal medicine/ 
excipient exposure, the extensive trade name list from the SES allows identi-
fication of substitution possibilities, while individual exposure data from the 
PPS provide a more precise quantification of the problem. Investigators need to 
balance the advantages of a PPS with the risk of bias, which depends on the 
frequency as well as the duration of medicine use. Simultaneous use of both 
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methods with merged data analysis will likely result in optimal coverage of both 
aspects of the problem. 
 
 
Figure 13. Correlation between medicines exposure at unit and individual levels 
Number of units using each specified active ingredient (n = 99) in relation to the number of 
prescriptions in the PPS was observed. Polynomial regression trendline for active pharmaceutical 
ingredients used in more than one unit in the SES is shown. √number of prescriptions = 0.421 * 
(number of departments) – 0.004 * (number of departments)2 + 0.485; R2 = 0.93 
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6. GENERAL DISCUSSION 
Neonates are routinely given medicines with no specific paediatric information 
because of the lack of clinical trials in this population. The status of children as 
“therapeutic orphans”217 has been increasingly recognised and has lead to a 
number of legislative initiatives in developed countries, including the US and 
EU over the last decades. The concept of the therapeutic orphan originates from 
1962. The first objective evaluation of labelled drugs available for children was 
done in 1973 with further continuum of validations from multiple sources.217 As 
a result, substantial unlicensed and off-label use of adult medicines in neonatal 
population has been actively addressed.18,28 Pharmaceutical excipients were 
called “inactive ingredients” just a little while ago46 with little attention paid to 
excipients safety until recently. Only from 2007 Paediatic Regulation requires 
excipient safety to be also considered by pharmaceutical industry when devel-
oping new medicines.218,219 While safety issues related to the use of some 
excipients in neonates raised concerns, data regarding the scope of the problem 
on a large scale were not available to date. In this thesis, we aimed to address 
the excipient exposure via an integrated risk assessment approach to identify the 
extent of the problem (excipient use), determine related risk factors and propose 
possible solutions. 
 
 
6.1 Unexplored field of pharmaceutical excipients  
in neonates 
Although extensive work has been done by pharmaceutical companies to ensure 
that excipients are safe when used in adults, their safety in paediatric subpopu-
lations is often unknown; some of them are known to be toxic and uncertainty 
about others, especially in neonates, exists.57 In an analysis, carried out by EMA 
Paediatric Committee, of paediatric investigation plans (PIP) proposed in 2009, 
issues with excipients were identified in 102 (82%) out of 125 pharmaceutical 
forms – applications included insufficient justification of the chosen excipients 
related to age, daily dose of excipient(s), and inadequate discussion on the 
possibility to replace excipients with potential safety concern.218 Currently, only 
30% of PIPs include studies with neonates.220 Comprehensive data about 
excipients included in medicines used in neonatal units is lacking and doctors 
are still prescribing medicines to neonates without knowing what excipients are 
included, whether they are safe, and whether there are opportunities/ needs to 
avoid excipients with safety issues. 
This was the first study looking at neonatal administration of pharmaceutical 
excipients in a large multi-country setting and the biggest and most detailed 
prospective study of excipient use in neonates to date. Previous studies on 
excipient exposure among neonates were conducted within single unit/ 
country.14–16,134,150,221 While frequent general administration of potentially 
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harmful excipients was emphasized, some results were contradictory probably 
due to small sample size and therefore cannot be extrapolated to the whole 
population. While Fister et al. showed no benzyl alcohol in medicines 
prescribed in Slovenian neonatal unit,16 Garcia-Palop et al. reported this to be 
one of the most common EOI prescribed parenterally to neonates in Spain.150 
We found benzyl alcohol in both enteral and parenteral commonly prescribed 
drugs, e.g. enteral colecalciferol and iron and parenteral phytomenadione, 
phenobarbital, hydrocortisone, heparin, and amoxicillin. 
In this study, data on the surprisingly broad range of medicines with highly 
variable excipient compositions, used in neonates in Europe, have been 
collected. Similarly to previous single country/ unit studies on excipient 
administration15,16,135 we demonstrate that a substantial part (63%) of neonates 
treated in European NICUs is exposed to potentially harmful excipients called 
here EOIs.214 Additionally, our data on both prescription and individual level 
showed that in particular the most commonly used medicines (e.g. gentamicin, 
iron, enteral vitamins) were responsible for a large part of the EOI “load” 
suggesting that substitution or reformulation of a relatively small number of 
medicines may spare a large number of neonates from unnecessary exposure. 
Another element of exposure assessment not studied in this work is 
quantitative, i.e. understanding of excipient exposure patterns also requires 
descriptions of excipient kinetics comparable to PK for APIs. Recent obser-
vational studies suggest that neonates are exposed to significant amounts of 
excipients, some of which can exceed internationally recommended limits for 
exposure.14,134 However, there have been very few attempts to measure 
excipients quantities in the bloodstream and assess PK parameters in neonates – 
the main impediment has been a limited amount of blood volume allowed for 
sampling. Most excipient exposure studies, including those presented in this 
thesis, measured exposure indirectly through prescription data. To date, only a 
couple of studies have been performed with the aim to estimate blood levels or 
PK parameters of excipients with known safety concerns – benzyl alcohol by 
LeBel et al. and propylene glycol by Roosmarijn et al. – in neonates using 
“wet” sample-based assays.7,78 Although dry blood spot (DBS) method allows 
determination of drug levels in very small blood volumes,222–226 this methodo-
logy has not been used before the ESNEE project to measure excipient (i.e. 
parabens) PK parameters.227 Data collected during our study allowed to identify 
drug products containing methyl- and propyparabens with further inclusion of 
these medicines into PK study. 
Today, even if some data on the safety/ toxicity of excipients are available, 
these are not easy to find from public sources. Moreover, Lass et al. reported no 
human safety/ toxicity data accessible in the literature for 16% out of 123 
excipients identified in medicines prescribed to neonates in Estonia.15 Global 
Research in Paediatrics (GRiP) popularizes the need for a comprehensive 
source of computerized information concerning the toxicity and safety of 
excipients for paediatric medicines.228 To address this need, the European and 
US Paediatric Formulation Initiatives (Eu-US PFIs) are working together to 
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create and maintain a database of Safety and Toxicity of Excipients for 
Paediatrics (STEP) – evidence-based database addressing safety issues and 
toxicity aspects of pharmaceutical excipients in medicines for children.229 The 
purpose of STEP is to serve as a free database for safety data and supporting 
toxicity studies for excipients, particularly in paediatric population. 
A newly launched project “Safe Excipient Exposure in Neonates and Small 
Children” (SEEN) aims to explore the quantity of excipient exposure in 
neonatal and young paediatric patients in a Danish Hospital focusing on 
excipients known to be harmful.230 Both registered and extemporaneous 
pharmaceuticals as possible sources of excipients will be studied. The success 
of this doubtless important study will depend on whether the manufacturer of 
each medicinal product included in the study will provide needed quantitative 
information on excipient content. 
 
 
6.2 Methodological issues of the excipient exposure study 
To date, generally accepted tools for excipient exposure assessment have not 
been identified. Most available tools for pharmacoepidemiologic studies, i.e. 
hospital or health insurance databases, lack details required for assessment of 
excipient exposure. Study designs allowing coverage of large study populations 
over relatively short period and limited dataset appear appropriate for initial 
estimation of the scope of the problem. In this thesis, to assess the exposure to 
excipients, we had to gather data about prescribed medicines first. The precision 
of estimation of the extent and nature of neonatal exposure to different 
medicines/ excipients was maximized by successive use of two different cross-
sectional study designs, the SES and PPS – the first providing a comprehensive 
list of medicines/ excipients used in neonates and the latter adding detailed data 
on individual exposure. The strength of both methods used in this thesis is the 
simplicity and uniformity of data collection. In the SES the most time-
consuming part of data analysis turned out to be the identification of excipient 
content from SmPC for each single drug product. Such approach is probably not 
sustainable for future researchers. Hence, time and resource consuming devel-
opment of new tools, like the web-based prepopulated database in our study 
and/ or hospital electronic prescription databases including also excipient data, 
may prove necessary. Furthermore, given the possible organisational and eco-
nomic implications, market size making these feasible (e.g. drug reformulation 
or substitution) should be aimed/ involved as in our study. Simple data structure 
used in the SES improved recruitment in general, while more detailed data 
capture, when facilitated by prepopulated tool as in the PPS appeared more 
attractive for physicians from teaching hospitals, usually taking care of more 
complex patients with broader spectrum of medicines used. However, as 
showed in our study, longitudinal component is needed to capture less 
commonly used medicines. 
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Data structure should be chosen in compliance with the research question. A 
study with the primary aim of describing the variability/ comprehensive list of 
medicines or excipients administered for short time periods may allow less 
sophisticated data structure/ volume to be reported, with additional benefit of a 
longitudinal component to maximise study power. When individual exposures 
of frequently used medicines are targeted, the increasing data volume (both 
structure and duration) needs to be weighed against evolving increase in 
resource consumption and possible decrease in compliance that may lead to 
underestimation of prevalence.231 It has been shown that the longer the recall 
period, the greater the imprecision (especially underestimation) of prevalence 
estimates,232,233 although this finding may be more relevant in non-medical 
informants.234 Oppositely, short-term surveys like SES and PPS conducted on a 
single unit/ country level are likely to underestimate the extent and variety of 
medicines/ excipient exposure.235 Instead, single country/ unit long term cohort 
studies may provide valuable complementary information as described by Lass 
et al.,15,24 allowing more detailed individual risk assessment including 
quantitative/ cumulative exposure estimation, where wanted.14 
Alternatively to our approach, nested study designs with longitudinal data 
collection would allow linkage between different datasets and could be the best 
option. In our study, nested design with detailed individual data collection 
performed as part of the SES was not feasible, as an interim between the two 
studies was needed to develop the prepopulated PPS medicines database from 
the data collected in the SES. This could potentially reduce the overlap between 
the studies. In that situation our data represent a “worst case scenario”. The 
actual concordance in API reporting may be higher than described by us. To the 
best of our knowledge, nested design has hardly been used in paediatric 
pharmacoepidemiological studies. 
Not only optimal recruitment of participants but also sample size main-
tenance over the course of a study becomes an issue, especially in multinational 
studies.236 Recruitment of participating NICUs, regional distribution, and 
variability in levels of care and unit size should be considered.57 As random 
recruitment is often unfeasible, cluster sampling approach was planned in the 
PPS.237 Recruitment of randomly chosen regional clusters based for example on 
the EuroStat NUTS classification would have allowed adjusting for the 
variability of levels of care in NICU studies. Still in cluster design the cluster 
effect and intracluster coefficient of variance need to be considered.57 Involve-
ment of all units from chosen region is needed to achieve estimated sample size 
for each country and region and to ensure the randomisation and represen-
tativeness of the data. In our study, randomisation of participating hospitals 
remained unfeasible due to the lack of a full list of neonatal units in each 
country. Additionally, it is hardly possible to achieve 100% response rate in 
such a wide scale study.196–199 
While pharmacoeconomic analysis remains beyond the scope of this study, 
economic considerations always play a role in the choice of a specific study 
design. There were no major cost differences in conducting the SES and PPS 
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studies except those associated with the development of the PPS database 
specifically for this study. Web-based data collection with automated checks 
allowed to save resources and to improve compliance and overall quality of 
data. We believe that whenever adequate to answer the research question, the 
simple data structure is favourable in terms of resource allocation. However, 
when a more complex format is required, reasonable additional expenditure on 
data collection tools may result in an improved cost-benefit ratio. We have 
shown that under the condition of limited resources, individual exposure 
estimates can be extrapolated from a less demanding approach like the SES. 
However, such extrapolation does not allow stratification by demographic 
characteristics, that is of great importance in the neonatal population. 
 
 
6.2.1 Availability of excipient data in current sources 
 
“Omnia venenum sunt, nec sine veneno quicquam existit; dosis sola facin ut 
venenum non sit.” (In practice, every substance is a poison, at the right dose. 
Paracelsus; 1493–1541) 
 
Even today, collecting information on the content of excipients in drug 
formulations remains a challenge. In this thesis, SmPC proved the most reliable 
data source because excipients present even in tiny amounts have to be 
included.163 Nevertheless, in our study SmPC were unattainable for 13% 
(n=138) of products, leaving the practitioners with little if any reliable grounds 
to take decisions. Moreover, information about the composition of compound 
flavours is usually not included in SmPC; even in specialized pharmaceutical 
databases only qualitative data are presented: http://www.theriaque.org/apps/ 
monographie/index.php?type=SP&id=6826. The information on excipients still 
not being readily available to the clinician derives from two main principles. 
Firstly, some medicines package inserts list no excipients, or the list is 
incomplete, ignoring regulatory requirements, for historical or inconvenience/ 
data availability issues. Secondly, manufacturers are not open to disclose this 
information, especially when quantitative content is concerned, claiming 
business confidentiality.238 We identified reports stating that a full list of 
excipients was not available as part of the protection of intellectual property. 
Guidances and recommendations from Regulatory Authorities regarding the 
inclusion of potentially harmful excipients in drug products intended (labelled) 
for use in children/ neonates are increasing in both the US and EU. Since 2010 
disclosure of quantitative data on excipients with safety concerns has been 
required. Woefully this initiative will address only a small proportion of new/ 
newly authorised products for neonates while the majority of medicines are still 
prescribed off-label or unlicensed. In our study quantitative excipient 
information was available from SmPC in only 6% (n=58) of products. Notably, 
more than half of these products did not contain any EOI; among all products 
with EOI quantitative data were available for only 8% (25/305). Like us, Fister 
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et al. found insufficient data on the quantities of excipients in products 
administered to neonates.16 
Making at least comprehensive qualitative but preferably quantitative 
excipients data available to healthcare professionals holds an opportunity to 
make “safer” choices. Knowledge of quantitative data would better guide the 
selection for only those products where replacement is an absolute necessity. 
 
 
6.3 Rationality of adding EOI into medicines 
Assessment of the rationality of excipient administration is a complex task 
involving multiple manufacturing as well as formulation target/ use related 
details, e.g. route of administration. Many excipients have the potential to fulfill 
multiple roles within a single or in different formulations. We believe that 
certain abstraction can be reached based on the (main) purpose of an excipient 
in a formulation, accepting that these assumptions can never be exhaustive. The 
pattern of covariates associated with the administration of EOI in our study 
suggests rational use in many medicines, while for some a margin for improve-
ment is proposed and supported by availability of substitution possibilities. 
Based on available data we hypothesised that solvents (polysorbate 80, 
propylene glycol, ethanol) are required for manufacturing process of a specific 
API not soluble in the water or other liquids.48,149 In contrast, we showed that 
polysorbate 80 and propylene glycol use was associated with geographical 
region and enteral route of administration even after adjusting for potential 
covariates, including ATC group as a surrogate for API. Our results suggest the 
possibility to use/ produce medicines free of these excipients in one but not 
another country/ region. Although some regional variations may be driven by 
differences in API within the ATC group (e.g. enteral vitamins), many likely 
rise from hospital routines and policies. The latter is often based on traditions 
and expert opinions rather than evidence-based guidelines.24,28,136 No regional 
variations were associated with administration of ethanol, found predominantly 
in enteral formulations, referring to its rational use. Nevertheless, we identified 
either enteral (i.e. colecalciferol, furosemide, iron, nystatin) or parenteral (i.e. 
metronidazole, phenobarbital, ranitidine) ethanol-free alternatives for all enteral 
ethanol-containing products. In some cases, judging the rationality of excipient 
use requires careful weighing of possible additional risks of an alternative 
formulation (e.g. different route of administration) against those related to 
excipient exposure. 
Antimicrobials (parabens, benzoates, benzalkonium chloride) should not be 
required for sterile single-dose parenteral formulations. Accordingly, parenteral 
route was associated with lower administration of these excipients – 85% of 
parenteral prescriptions were paraben- and benzoate-free. The presence of 
parabens and/ or benzoates in 15% of parenteral prescriptions may suggest the 
use of multiple-dose formulations or, that some medicines require these 
excipients for other than antimicrobial, like manufacturing and stability pur-
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poses. No conclusions can be made regarding the first explanation as data on 
single- or multiple-use were not available in SmPC. Therefore we propose this 
information to be included on the drug label and patient information leaflet. We 
can speculate that among frequently used APIs with antimicrobials dexa-
methasone (4 mg/ml), epinephrine (1 mg/ml), and gentamicin (80 mg/2ml) are 
single-use formulations. We found same strength products without any EOI for 
all above-mentioned APIs. In addition, we identified EOI-free alternatives for 
several commonly used enteral products containing antimicrobial EOI – 
amoxicillin, caffeine, colecalciferol, folic acid, iron, and tocopherol – indicating 
possibility to produce enteral liquid medicines, e.g. in the form of powder for 
reconstitution, without antimicrobials. 
Sweeteners (sorbitol, saccharin sodium) were expected to vary only between 
routes of administration and GA. This was true for sorbitol; rational use was 
supported by the association with term GA, the extent of use being independent 
of geographical region and a lower rate in parenteral formulations. Among 
commonly used APIs sorbitol-free enteral products were available only for iron. 
The use of saccharin sodium, found almost exclusively in enteral medicines, 
varied between geographical regions, suggesting the availability of saccharin 
sodium-free formulations on the European market (e.g. iron and furosemide). 
One could also question the rationality of adding colouring and flavouring 
agents to formulations administered to premature neonates through a 
nasogastric tube. For example, strawberry flavour could contain 13 different 
substances including propylene glycol. As flavouring agents do not contribute 
to functions other than palatability,37 their use can be avoided in products aimed 
at patients/ situations, where this is not relevant e.g. due to the method of 
administration. 
 
 
6.4 Substitution as a way of avoiding EOI 
Substitution of EOI-containing products with EOI-free formulations already 
available on the market is attractive33 as the risks of importing and using 
licensed medicines are much lower than those associated with extemporaneous 
preparations.182 To examine the feasibility of this approach, searches for 
alternative medicines with the same API, route of administration and dosage 
form have been done in this work. We have shown that EOI-free formulations 
are workable and available on the European market offering alternative to EOI-
containing products in many cases. For example, we have put in use paraben-
free parenteral gentamicin formulation in our neonatal unit in Tartu University 
Hospital. 
Compared to parenteral formulations finding EOI-free alternatives for 
enteral products proved more complicated probably due to common use of 
multidose formulations and need to improve palatability. Accepting parenteral 
route of administration instead of enteral may be needed to avoid EOI 
administration. We recognise that switching to parenteral administration if the 
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oral route is available may pose unnecessary risks.215,239 WHO has suggested the 
change of product, dosage form or even route of administration to be 
occasionally justified to avoid significant risk posed by excipients known to be 
toxic.2,33 
Manufacturers should adopt existing best practices of safe and efficient use 
of excipients at the global level.59 For example, if ethanol can be removed from 
certain oral liquid medicines in one country,59,119 it should be carried out 
globally. We accept that there is a minimum set of excipients needed. However, 
our work indicated that 11 out of 12 parenteral and nine out of 17 enteral 
frequently used APIs do not need EOI to be included in the manufacturing 
process a priori. Changes in manufacturing processes to avoid EOI are possible 
without altering the pharmaceutical quality of the medicine.57 
Klingmann et al. have shown the administration of uncoated mini-tablets to 
be a valuable alternative to syrup in term neonates.240 This may be part of a 
strategy to avoid some toxic excipients, e.g. sweeteners, solvents, antimicrobial 
preservatives. Developing new products for the market is time-consuming and 
costly. The reformulation of ibuprofen or caffeine has resulted in products that 
are significantly more expensive than unlicensed alternatives. Such products 
may remain out of the reach of many NICUs, especially in less privileged 
countries.241 Therefore, considering the concomitant costs related to the 
development of age-appropriate EOI-free medicines, neonatal formulations 
need to be limited to those that are absolutely needed. We have shown a 
significant potential to reduce neonatal exposure to EOI through substitution of 
only frequently used medicines with EOI-free alternatives available on the 
European market. 
We recognise that implementation of systematic product substitution into 
every-day practice is not straightforward and can be only a part of an all-
embracing strategy to provide safe and effective pharmacotherapy for 
neonates.57 Even substitution with existing EOI-free products may incur 
additional costs due to the complexity of the requirements to be considered in a 
process involving multiple stakeholders (e.g., regulatory, financial, clinicians, 
etc.). If products are currently marketed in one European country, barriers to 
product substitution relate to licensing, distribution and marketing costs.215,218 
These costs may outweigh expected market return in small countries. 
Nevertheless, the knowledge of EOI-free products for a substantial number of 
APIs available in one but not other EU countries deserves further consideration 
by licensing authorities and should stimulate manufacturers, researchers, and 
healthcare professionals to make these products available in each country. 
Cooperation to ensure mutual consideration of data to allow licensing in all 
European countries is needed. Free movement of medicines inside the European 
market and committed collaboration between practitioners and stakeholders that 
extends across regions and countries becomes essential.215 
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6.5 Limitations of the study 
Some limitations of the current thesis should be acknowledged. Out of the 31 
invited countries, about two-thirds participated in each study, omitting some 
large European countries (e.g. Germany). Also, inability to randomly select 
hospitals has to be borne in mind. However, we believe that identified excipient 
administration patterns are appropriately adjusted and could be extrapolated to 
the European cohort. 
Neonatal units were given the option of selecting the most appropriate day(s) 
for data collection. This could lead to underestimation of medicine use because 
less busy day(s) were probably more likely chosen. However, we believe that 
eventually this approach captured information on a larger number of neonates 
and medicines through improved compliance and a larger number of participating 
units. 
Our study included eight excipients known to be harmful in neonates leaving 
a substantial number of excipients classified as potentially harmful, unexplored. 
We believe, that assuming the reformulation/ substitution processes not to be 
straightforward, those medicines containing the most problematic excipients 
should be studied first. 
In risk factor analysis grouping of API to the 1st level of ATC classification 
only, with the exception of antibiotics, was feasible due to the relatively small 
number of prescriptions. Therefore some effects may be driven by intra-level 
variations in API use. These limitations still do not undermine the significance 
of regional variations, although may explain some findings on GA level. 
As underlined before, the lack of quantitative information on excipient 
content in medicines did not allow detailed conclusions on quantitative exposure 
to EOI. Although this does not undermine our findings, large-scale quantitative 
exposure assessments are missing. 
We recognise, that due to the general deficiency of age-appropriate formu-
lations for neonates products used for substitution may not always be age-
appropriate for this age group. We did not study the stability and validity of 
different formulations in detail and assume, that products prepared in different 
pharmacies may have variations in stability and shelf-life. Still, by identifying 
the substantial capacity for product substitution among marketed formulations 
in actual use in neonatal units, we believe this concept as a way to reduce EOI 
exposure in neonates well proven. Here, close collaboration of all stakeholders 
is required to resolve the technical and logistical issues surrounding practical 
achievement of substitution, such as import restrictions, legal and supply issues 
relating to off-label or unlicensed medicines, cost, age-appropriateness, dose 
volume and dose flexibility, interchange of route of administration, and 
prevention of medication errors. Economic and regulatory aspects of product 
substitution were out of the scope of the current analysis and need further 
evaluation. 
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6.6 The need for further research 
An ideal neonatal prescription should represent an age-appropriate formulation 
of high pharmaceutical quality with appropriate knowledge on PK/ PD and 
safety profile of all compounds incorporated in a medicinal product. Future of 
age-appropriate formulations for neonates also involves excipients safety.32 
High rates of exposure to EOI in European neonates as was shown by us, 
underlines the relevance of the issue. We have proposed the way to reduce 
neonatal exposure to EOI through product substitution being fully aware this 
will not resolve the problem completely. If EOI-free formulation does not exist 
then careful balance between the evidence that an excipient may cause problems 
in the developing organism, especially in relation to the severity of patient 
condition, and expected benefit of the drug should be sought in each case; risk/ 
benefit ratio should be carefully weighted based on predicted dose, duration of 
exposure, and PK data. Limited data on the safety and/ or toxicity of excipients 
bind hand and foot in achieving this. Consequently, toxicokinetic research-
based risk assessment in neonatal population becomes paramount, to identify 
true needs for reformulation/ substitution or where this is not possible, defining 
safe practice recommendations. 
It is accepted that excipients may only show an effect above a certain dose98 
and the presence of an excipient in formulation does not necessarily mean 
(daily) intake exceeding the toxic threshold during routine treatment. To date, 
information on toxicity thresholds remains sketchy, especially in neonates. 
Need for excipient toxicokinetic studies has been increasingly recognised but 
only slow progress has been made so far.78,227,229 Until recently, PK data in 
neonates were available only for propylene glycol and ethanol. For example, 
Allegaert et al. and Kulo et al. showed, that propylene glycol administration 
with a median of 34 mg/kg/day for a maximum of 48 hours seems to be well 
tolerated in neonates and does not affect short-term postnatal adaptation.242,243 
However, in extremely preterm neonates accumulation of propylene glycol may 
occur with co-administration of currently used phenobarbital and paracetamol 
formulations – birth weight was found to be the most significant covariate for 
propylene glycol clearance.78 Similarly, we in the ESNEE clinical study have 
demonstrated low serum levels of parabens in neonates with some risk of 
accumulation only in the most preterm neonates.227 As exact safe/ toxic con-
centrations are still unknown, further information on excipient PK in neonates is 
needed to estimate the level of tolerance considering the number of potential 
covariates as GA, postnatal age, birthweight, disease characteristics, treatment 
modalities (e.g. whole body cooling), route of administration, polypharmaco-
therapy/ drug-drug, drug-excipient interactions etc..51 Toxicokinetic models 
should be developed to serve as a tool for individualised risk estimation in 
difficult to predict patient groups (e.g. organ failure, extreme prematurity). 
Studies in juvenile animals can provide relevant information, but cannot always 
be extrapolated to human neonates. To allow extrapolations, more complex 
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population pharmaco/ toxicokinetic studies, including physiology-based PK 
modelling, are needed. 
Valid long-term neurodevelopmental outcomes of administration of poten-
tially harmful excipients are entirely missing, even when favourable short-term 
outcome is demonstrated.242,243 The applicability of outcome variables/ indi-
cators applied to assess renal, hepatic and metabolic tolerance of administered 
excipients in adults needs to be validated in neonates.79 As excipients are 
interacting with the body and vice versa, clinical pharmacologists with expertise 
ranging from PD, PK, rational prescribing, adverse drug effects, and toxicology 
should be key players in advancing drug formulation issues in children.90 
Recent methodological advances including opportunistic sampling, popu-
lation PK approach, micromethods for substance level estimation and DBS have 
made neonatal PK studies feasible. The ESNEE project has shown the feasi-
bility of such methods for parabens.227 This means that it is now possible to 
examine the net effects of age-specific features of excipient disposition.79,244 
The assessment of potential excipient exposure can include direct evidence 
about the concentrations that results from prescribed medicines administered 
during clinical care. The inclusion of this information in risk assessment will 
reduce uncertainty and inform the development of safety margins.57 That, 
among other things, may save time and resources by identification of only those 
excipients/ excipient concentrations/ products where replacement or reformu-
lation is necessary. 
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7. CONCLUSIONS 
In the course of this research, a unique database of medicinal products used in 
neonates in European neonatal intensive care units (NICU) was created, which 
allowed us to assess the extent of excipients use, to determine related risk 
factors, and to offer possible solutions to reduce neonatal exposure to excipients 
of interest (EOI). 
 
The following specific conclusions can be drawn from this research: 
 
1. The two cross-sectional study designs used in this research have proven 
valuable complementary tools in assessing neonatal exposure to excipients, 
with good correlation between the two methodologies. Simple data structure 
and longer study period of the service evaluation survey (SES) allows better 
recruitment, resulting in more comprehensive overview of medicines used in 
NICUs. The frequency of use on unit level appears a good surrogate of indi-
vidual exposure rates. However, detailed information on individual exposure, 
including demographic variables, relevant in excipient associated risk 
assessment, can be collected in the point prevalence study (PPS). Suitable 
tool/ database development may be required prior to implementation. 
Combining different methods with merged data analysis will likely result in 
optimal coverage of different aspects of the problem. 
 
2. The broad range of medicines with over one thousand different products of 
highly variable excipient compositions administered to neonates in European 
NICUs highlights the relevance of excipient related research. Administration 
of excipients with known safety issues to neonates is common as a third of 
drug products, reported in our study, contained at least one EOI. Enteral 
medicines more likely contained all studied excipients except benzalkonium 
chloride. The largest number of prescriptions with parabens, benzoates, 
ethanol, sorbitol, and saccharin sodium was associated with enteral vitamins. 
This should be considered by clinicians when prescribing enteral formu-
lations to neonates; enteral vitamins should be included in the priority list of 
drugs requiring data in preterm and term neonates. 
 
3. Almost two-thirds of neonates were exposed to at least one EOI, over half of 
them received more than one. Gestational age (GA) related variations in 
excipient exposure were predominantly related to increasing prescription 
rate with decreasing GA and different active pharmaceutical ingredients 
(API) and formulations prescribed in different GA groups. Extreme 
prematurity was associated with higher exposure to EOI with antimicrobial 
properties (parabens and benzoates) compared to term infants, explained by 
the high use of parenteral antibiotics (i.e. gentamicin) and enteral multi-
vitamin preparations. Term infants more likely received products containing 
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solvents (polysorbate 80 and propylene glycol) and sweeteners (sorbitol) 
compared to extremely preterm neonates. This may reflect some degree of 
deliberate avoidance of EOI in extreme prematurity. 
Most commonly used medicines were responsible for most exposure to 
EOI, meaning that substitution or reformulation of a relatively small number 
of products would significantly reduce neonatal exposure. 
 
4. Significant geographical variations were found in the use of EOI, inde-
pendent of excipient functional class. Compared to the eastern region, the 
likelihood of paraben exposure was higher in the southern and northern, and 
of polysorbate 80 and propylene glycol lower in the southern and northern 
region, respectively. In contrast, exposure to saccharin sodium was the 
lowest in the eastern compared to all other regions. Geographical variations 
in the use of studied excipients suggest availability of EOI-free medicinal 
products and potential to reduce exposure through product substitution. 
 
5. Two-thirds of the medicinal products containing EOI could be substituted 
with EOI-free medicine of the same API and dosage form. Substitution of a 
relatively small number of frequently used products would spare almost half 
of currently exposed neonates. The overall cumulative gain may be even 
greater as in many cases if not completely avoiding, substitution would 
reduce multiple administration of EOI. Our data support the rational use of 
studied excipients in many cases, but significant improvement is still 
possible without major reformulation costs. There is a need for common 
European market with free movement of medicines between different 
countries that will contribute to better product substitution opportunities and 
stimulate product reformulation if needed. 
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9. SUMMARY IN ESTONIAN 
Abiainete kasutamine vastsündinutele manustatavates  
ravimites Euroopas 
Ravimite tootmisel on lisaks toimeainele vaja kasutada erinevaid farmatseutilisi 
abiaineid. Abiained on kõik ravimi koostisosad v.a. toimeaine: lahjendajad, täite-
ained, lahustid, emulgaatorid, sideained, disintegrandid, magusained, säilitus-
ained, lõhna- ja värviained. Farmatseutilises tehnoloogias kasutatakse üle 
tuhande erineva abiaine, mis moodustavad keskmiselt 90% ravimvormi 
massist.2 Abiainetel on ravimvormis/ ravimpreparaadis erinevaid funktsioone ja 
nad on vajalikud ravimite säilitamiseks, välimuse ja maitseomaduste paranda-
miseks, erinevate ravimvormide väljatöötamiseks, biosaadavuse parandamiseks 
jne.1 
Ravimi ohutus on alati olnud prioriteediks, palju tähelepanu pööratakse ees-
kätt toimeaine kvaliteedile, efektiivsusele ja ohutusprofiilile. Abiainetel on oma 
kindel funkstioon ravimvormis ning seega on neil kindlad füsikokeemilised 
omadused. Viimasel ajal on üha selgem, et ka abiained võivad olla kõrval-
toimete põhjustajaks.3–6 Tõsiste kõrvaltoimete kõrval võivad abiained põhjus-
tada talumatust, allergiat ning ravimi toimeaine efekti vähenemist. 
Arvestades ainevahetuse iseärasusi on teatud abiainete kasutamisega seotud 
riskid enam väljendunud vastsündinutel, kelle kesknärvisüsteem ja teised elu-
tähtsad organid ei ole veel lõplikult arenenud10. Seetõttu võivad teatud ainete 
minimaalsedki annused põhjustada tõsiseid kõrvalekaldeid organite funkt-
sioonis ja arengus.13 Näiteks on varajases sünnijärgses perioodis kesknärvisüs-
teem erakordselt vastuvõtlik mõnedele neurotoksiinidele nagu propüleenglükool 
ja etanool.75 Ainevahetuse ja organfunktsioonide iseärasusest tulenevalt on vast-
sündinutel võrreldes vanemate laste ja täiskasvanutega erinev ka manustatavate 
ainete s.h. abiainete farmakokineetika ja farmakodünaamika. Lisaks on vast-
sündinute, eriti enneaegsete puhul, sageli tegemist polüfarmakoteraapiaga; 
üheaegselt kasutatavate ravimite hulk on tugevas korrelatsioonis kõrvaltoimete 
tekkega.130 Ühe metaboolse raja (nt. alkoholi dehüdrogenaas) mitme erineva 
substraadi (nt. propüleenglükool ja etanool) koos manustamine võib põhjustada 
toksilise aine (propüleenglükool) kuhjumist organismis.9 
Vastavalt Euroopa Ravimiameti (EMA; European Medicines Agency) juhen-
dile vastsündinutele ravimite väljatöötamiseks tuleb siin „erilist tähelepanu 
pöörata abiainete valimisele, kuna paljud nendest võivad olla toksilised”.18 
Kuigi on andmeid, et mõned abiainetest võivad olla vastsündinutele toksilised 
ning põhjustada haigestumist või surma, puuduvad selle kohta põhjalikud üle-
vaated ning süstemaatilisi uuringuid on vähe. Üksikud uuringud on näidanud, et 
vastsündinutele manustatakse abiaineid märkimisväärsetes kogustes, mis sageli 
tunduvalt ületavad soovituslikke maksimumannuseid.14,134 Lass et al. näitasid, et 
Eesti kahes neonatoloogia osakonnas manustati poole aasta jooksul 88%-le 
vastsündinutest vähemalt ühte teadaolevate kõrvaltoimetega abiainet.15 Sarnased 
tulemused saadi ka Souza et al. poolt Brasiilias135 ja Fister et al. poolt Sloveenias 
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läbi viidud uuringutes.16 Üksikute riikide/ osakondade uuringud osutavad 
probleemi olemasolule, kuid ei võimalda hinnata selle tegelikku ulatust. Põhja-
likud kogu Euroopat hõlmavad andmed abiainete kasutamise kohta vastsündinutel 
seni puuduvad. Samas võimaldaks need edaspidi planeerida meetmeid ohtlike 
abiainete kasutuse vähendamiseks vastsündinutel kasutusel olevate ravimite 
sobivama abiainete koostisega preparaatidega asendamise ning vajadusel ja 
võimalusel ka uute vastsündinutele mõeldud ravimvormide välja töötamise teel. 
Vastsündinutel kasutatavate ravimite rahvusvaheliste uuringute läbiviimiseks 
võib kasutada erinevaid vaatlusuuringute liike, kuid mitte kõik farmakoepi-
demioloogias kasutatud meetodid ei sobi abiainete ekspositsiooni uuri-
miseks.57,139 Abiainete koostis erineb ühe toimeaine erinevate ravimpreparaatide 
vahel ja seega tuleb spetsiifilise ravimpreparaadi identifitseerimiseks regist-
reerida andmed nii toimeaine kui ka raviminimetuse, ravimtootja, ravimvormi ja 
manustamisviisi kohta. Abiainete manustamise kvantitatiivseks hindamiseks on 
lisaks vaja koguda detailsed andmed ravimkorralduse (annus, manustamissage-
dus ja -kestus) ning patsiendi demograafiliste parameetrite kohta. Läbilõike-
uuringuid võib teostada kahel viisil. Esiteks, osakonna tasemel küsimustiku 
vormis, mis hõlmaks võimalikult palju osakondi ja annaks ülevaate kasutata-
vatest ravimitest ja abiainetest. Teiseks, hetklevimusuuringu vormis, mis kirjel-
daks individuaalset ekspositsiooni ja selle variatsioone. Siiski on vähe teada 
erinevate uuringu metoodikate mõjust uuringu tulemustele vastsündinutele abi-
ainete manustamise hindamisel. 
 
Uurimistöö eesmärgid 
Projekti peamisteks eesmärkideks oli iseloomustada ravimites esinevate teada-
olevate kõrvaltoimetega abiainete (edaspidi EOI, excipients of interest) kasuta-
mise ulatust Euroopa vastsündinute osakondades, teha kindlaks nende manusta-
misega seotud riskifaktorid ning hinnata ravimite asendamise võimalusi 
vähendamaks vastsündinute ekspositsiooni nendele abiainetele. 
 
Konkreetsed eesmärgid 
1. Selgitada välja kahe erineva uuringu metoodika nõrgad ja tugevad küljed 
Euroopa vastsündinutele manustatavate ravimite/ abiainete uurimisel 
2. Koostada andmebaas Euroopa vastsündinutel kasutatavatest ravimitest ja 
abiainetest 
3. Kirjeldada EOI manustamist ja seda mõjutavaid tegureid Euroopa vast-
sündinutel, selgitamaks välja kõige suurema riskiga olukordi 
4. Kirjeldada geograafilisi ja osakondade vahelisi variatsioone EOI manusta-
mises 
5. Välja selgitada sageli kasutatavate toimeainete EOI sisaldavate ravimprepa-
raatide asendamise võimalused Euroopa turul olemasolevate neid abiaineid 
mitte sisaldavate preparaatidega. Järgnevalt hinnata nende abiainete 
vastsündinutele manustamise vähenemist juhul, kui kõik ravimpreparaatide 
asendamisvõimalused oleksid rakendatud 
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Metoodika 
Uuringu eesmärkide saavutamiseks viisime läbi järgmised uuringud: 
1. Kolmepäevane uuring Euroopa vastsündinute osakondades (service eva-
luation survey, SES), mille käigus registreeriti 3 päeva jooksul kõik vast-
sündinutele manustatavad ravimid. Iga ravimi puhul koguti andmed ravimi 
tootja, kaubandusliku nime (trade name), toimeaine, toimeaine kontsentrat-
siooni, ravimvormi ja manustamisviisi kohta. Uuring viidi läbi 30.05.2011-
30.09.2011. 
2. Ühepäevane hetkelevimusuuring (point prevalence study, PPS) Euroopa 
vastsündinute osakondades, mille käigus veebipõhises keskkonnas regist-
reeriti kõik vastsündinutele manustatavad ravimid koos patsiendi demo-
graafiliste andmete (sünniaeg, sugu, APGARi hinne, gestatsioonivanus, 
sünnikaal, kaal uuringu päeval, organpuudulikkused) ning ravimi annusta-
mise detailse informatsiooniga (ravimi tootja, kaubanduslik nimi, toimeaine, 
toimeaine kontsentratsioon, ravimvorm, manustamisviis, annus ja intervall, 
ravi algus). Uuring viidi läbi 01.01.2012-30.06.2012. 
 
Uuringutes registreeriti kõik ravimid v.a. verekomponendid, glükoosi ja elektro-
lüütide lahused, vaktsiinid, piimasegud, rinnapiima rikastajad, taimsed prepa-
raadid ja käsimüügis olevad toopilised preparaadid. Lisaks ravimiinfole kogusime 
uuritavatest vastsündinute osakondades info osakonna ja teeninduspiirkonna 
suuruse, osakonna struktuuri ja haigete arvu kohta. 
Osalema kutsuti kõik Euroopa Liidu riigid, lisaks Šveits, Island, Norra ja 
Serbia. Osakondade uuringutesse kaasamise ja andmete registreerimisega tege-
lesid igas riigis kohalikud koordinaatorid. Uuringutesse kutsuti kõik vastsündi-
nutega tegelevad osakonnad, kus vastsündinud moodustasid >50% osakonna 
patsientidest, andmed koguti vastsündinute kohta vanuses kuni 28 päeva (k.a.). 
SES ja PPS uuringute andmete statistilisel töötlusel kasutasime nii 
kirjeldavat statistikat kui ühe- ja mitmemõõtmelist regressioonanalüüsi. 
Ravimite ekspositsiooni võrdlesime SES uuringus osakonna ja PPS uuringus 
nii osakonna kui ka individuaalsel tasemel. Kahe uuringu võrdlusanalüüsis 
kasutasime mitmetasandilise regressioonanalüüsi (multilevel mixed effects logistic 
regression models with crossed random effects). Tulemused olid kohandatud 
geograafilisele regioonile (Põhja-, Lõuna-, Lääne- ja Ida regioonid)204 ja 
osakonna raviprofiili tasemele (esimene, teine ja kolmas etapp)201,202 kui potent-
siaalselt segavatele teguritele, mis tehti kindlaks ettevalmistavas Poissoni popu-
latsiooni regressioonanalüüsis, mis hõlmas 10 sagedamini kasutatavat toime-
ainet. Võimalust hinnata individuaalset ekspositsiooni läbi osakonna eksposit-
siooni vaatasime kasutades polünomiaalset regressioonanalüüsi. 
SES ja PPS uuringus kogutud ravimite abiainete koostise leidmiseks tööta-
sime läbi vastavate riikide ravimiinfo materjalid ja ravimite veebipõhised 
andmebaasid. Kui nendes puudus infomatsioon vastava ravimi kohta, siis 
küsisime andmeid uuringus osalevatest haiglatest. Üksikutel juhtudel saime 
infomatsiooni abiainete kvantitatiivse koostise kohta nende tootjatelt. 
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Edasine detailne analüüs hõlmas kaheksa EOI, mis valiti põhinedes olemas-
olevatele toksikoloogilistele andmetele. Siia kuulusid polüsorbaat 80, propü-
leenglükool ja etanool, mida valdavalt kasutatakse lahustuvuse parandamiseks; 
parabeenid, bensoaadid ja bensalkooniumkloriid, mida kasutatakse tänu nende 
antibakteriaalsetele omadustele, ning maitseparandajad naatriumsahhariin ja 
sorbitool. 
Vastsündinutele manustatud EOI mahu ja individuaalse ekspositsiooni ise-
loomustamiseks kasutasime kirjeldavat statistikat ja ühemõõtmelist regressioon-
analüüsi, et välja selgitada potentsiaalsed EOI manustamist mõjutavad tegurid. 
Erinevate faktorite mõju abiainete kasutusele uurisime kasutades nii lapse-
põhiseid kui ka ravimkorraldustel põhinevaid binomiaalseid logistilisi sega-
mudeleid, mis olid kohandatud järgmistele ühemõõtmelises regressioon-
analüüsis kindlaks tehtud potentsiaalselt segavatele teguritele: geograafiline 
regioon, gestatsiooni vanus (<28 rasedusnädalat ehk erakordselt enneaegsed, 28 
kuni <32 rasedusnädalat ehk väga enneaegsed, 32 kuni <37 rasedusnädalat ehk 
hilised enneagsed, >37 rasedusnädala ehk ajalised vastsündinud)205 ja haigla 
tüüp. Ravimkorraldustel põhinev mudel kohandati lisaks ATC ravimklassile ja 
manustamisviisile. 
Ravimitele, mis sisaldasid EOI ja olid kasutusel rohkem kui 10% osakonda-
dest, hindasime asendamisvõimaluse olemasolu analoogsete ravimpreparaati-
dega, mis ei sisalda ühtegi EOI. Asendamisvõimaluste olemasolu uurisime 
kolmes etapis. Esimeses etapis pidi asendamiseks kasutatav ravimpreparaat 
olema sama toimeaine ja manustamisviisiga, teises etapis lisaks sama ravim-
vormi ja kolmandas etapis ka sama toimeaine kontsentratsiooniga. Teises etapis 
loeti kõik parenteraalsed ravimvormid (nt. lahus süstimiseks, pulber süstelahuse 
valmistamiseks) vastastikku asendatavaks; enteraalsete ravimite puhul olid 
asenduseks sobivad kõik vedelad ravimvormid (nt. suukaudne lahus, suukaudne 
suspensioon). 
Hindasime ravimpreparaatide asendamise potentsiaalset mõju (teise etapi 
kriteeriumite järgi) vastsündinute EOI ekspositsiooni mahule, kasutades lihtsat 
logistilist regressioonanalüüsi. 
 
 
Peamised tulemused 
Kokku osales SES uuringus 20 ja PPS uuringus 21 Euroopa riiki ning vastavalt 
115 ja 89 vastsündinute osakonda. SES uuringus registreeriti 313 toimeainet, 
1065 ravimpreparaati 332 tootjalt. PPS uuringus osales 1382 vastsündinut, 
kellest 726-le (52,5%) manustati 2199 ravimikorralduse alusel 562 ravimit. 
Ühtekokku hõlmas uuring 246 toimeainet. Oodatavalt kasutati enamust ravi-
mitest parenteraalselt (58%). Suukaudsed ja toopilised manustatavad ravimid 
moodustasid vastavalt 30% ja 12%. 
Võrreldes SES ja PPS uuringu metoodikat selgus kõrge omavaheline toime-
ainete kasutussageduste korrelatsioon kahe uuringu metoodika vahel osakonna 
tasemel (R2 = 0.8605; y = 0.6019x – 0.0053). Toimeaine kasutuse tõenäosus oli 
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SESis võrreldes PPSiga suurem (OR 2.36; 95% CI 2.05-2.73); seda mõjutas 
ravimi kasutamise sagedus ja kestvus, OR iga lisanduva kasutusprotsendi ja 
kasutamise lisapäeva kohta vastavalt 1.01 (95% CI 1.01–1.02) ja 1.02 (95% CI 
1.00–1.05). 
Polünomiaalses regressioonanalüüsis selgus igat toimeainet saavate laste ja 
seda kasutatavate osakondade osakaalude omavaheline kõrge korrelatsioon (R2 
= 0.93; √y = 0.421x – 0.004x2 + 0.485). 
Edasiselt uurisime detailsemalt abiainete kasutamist. Ühtekokku registreeri-
sime kasutatavates ravimites 396 abiaine sisaldust. Vaid 12% manustatud 
ravimpreparaatidest ei sisaldanud abiaineid, nendest valdav enamus (95%) olid 
mõeldud parenteraalseks manustamiseks. Kõigist ravimitest 306 (31%) 
sisaldasid vähemalt ühte EOI ning enam kui üks EOI esines 173 (17%) ravimis. 
Ootuspäraselt sisaldasid parenteraalsed ravimid EOI harvem kui suukaudsed 
(OR 0.12; 95% CI 0.09–0.17) ja lokaalselt kasutatavad ravimid (OR 0.16; 95% 
CI 0.11–0.26). Kõige sagedamini kasutatavad EOI olid parabeenid (43% vast-
sündinutest eksponeeritud), mille järgnesid polüsorbaat 80 (19%) ja propüleen-
glükool (17%). Ravitud vastsündinutest 65% (456/726) said vähemalt ühte 
teadaolevate kõrvaltoimetega abiainet. 
EOI kasutus oli seotud gestatsioonivanusega: parabeene, bensoaate ja 
etanooli kasutati ajalistel vastsündinutel (OR ja 95% CI vastavalt 0.5; 0.3–0.9; 
0.3; 0.1–0.8 ja 0.3; 0.1–0.7) ja etanooli hilistel enneaegsetel (OR 0.3; 95% CI 
0.1-0-9) erakordselt enneaegsetega võrreldes oluliselt vähem. Eelkõige oli see 
tingitud erinevate toimeainete kasutamisest erinevates gestatsioonigruppides, 
sest ravimkorralduste analüüsis, mis lisaks muudele faktoritele oli kohandatud 
ka ravimiklassile, ei olnud see mõju enam statistiliselt oluline. Seevastu, 
polüsorbaat 80 kasutati ajalistel ja hilistel enneaegsetel (OR ja 95% CI vastavalt 
11.3; 3.9–32.1 ja 3.02; 1.1–8.5) ja propüleenglükooli ja sorbitooli ajalistel 
vastsündinutel (OR ja 95% CI vastavalt 7.7; 2.98–19.8 ja 6.9; 1.6–29.8) 
erakordselt enneaegsetega võrreldes oluliselt rohkem. 
Mõnede abiainete kasutamises esinesid regionaalsed erinevused, mis jäid 
oluliseks ka võimalikele neid erinevusi põhjustavatele teguritele (gestatsiooni-
vanus, toimeaine, manustamisviis) kohandatud mudelis. Võrreldes ida 
regiooniga kasutati polüsorbaat 80 vähem lõuna (OR 0.03; 95% CI 0.002–0.6) 
ning propüleenglükooli põhja regioonis (OR 0.02; 95% CI 0.004–0.1), 
parabeene kasutati rohkem põhja ja lõuna (OR ja 95% CI vastavalt 2.97; 1.2–
7.1 ja 4.1; 1.6–10.6) ning naatriumsahhariini põhja, lõuna ja lääne piirkonnas 
(OR ja 95% CI vastavalt 32.7; 2.5–426.5; 101.3; 7.3–1403.6 ja 60.3; 4.2–
861.6). 
SESi andmebaasi alusel leidsime asendusvõimaluse analüüsi esimese, teise 
ja kolmanda etapi kriteeriumide järgi vastavalt 120/137 (88%; CI 81–92), 
91/137 (66%; 95% CI 58–74) ja 42/137 (31%; 95% CI 24–39) ravimile. Teise 
etapi asenduse kriteeriumeid arvestades on võimalik vähendada parenteraalselt 
ja enteraalselt manustatavate EOI sisaldavate toimeainete arvu vastavalt 12lt 
ühele (92% vähenemine; 95% CI 65–99) ja 17lt üheksale (47% vähenemine; 
95% CI 26–69). 
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Ainuüksi sageli kasutatavate ravimite asendamine vähendaks nende läbi EOI 
eksponeeritud vastsündinute arvu 85% (315-lt 46-le) ja kõigi EOI eksponeeri-
tute arvu 44% võrra (456-lt 257-le). Kõikide EOI, v.a. etanooli, sorbitooli ja 
naatriumsahhariini manustamise tõenäosus vähenes asendusvõimaluste arvesse 
võtmisel statistiliselt oluliselt. Alprostadiil oli ainus parenteraalne toimeaine, 
mille ravimpreparaatide hulgas puudus etanoolivaba ravimvorm. 
 
 
Järeldused 
Antud uurimistöö käigus on koostatud unikaalne andmebaas Euroopa vast-
sündinutel kasutatavate ravimite kohta, mis võimaldab hinnata abiainete 
manustamise mahtu vastsündinutel, identifitseerida seotuid riske ja näidata 
võimalikke lahendusi vähendamaks vastsündinute ekspositsiooni teadaolevate 
kõrvaltoimetega abiainetele. 
 
Uurimistöö konkreetsed järeldused: 
 
1. SES metoodika oma lihtsama andmestruktuuriga võimaldab kaasata rohkem 
vastsündinutega tegelevaid osakondi ja annab ammendavama ülevaate vast-
sündinutel kasutatavate ravimite ja abiainete nimistust. PPS annab võimaluse 
kirjeldada vastsündinute individuaalset ekspositsiooni ja kindlaks teha selle 
võimalikud riskifaktorid Euroopa riikides. Kahe erineva metoodikaga kogu-
tud tulemusi saab kasutada teineteist täiendavana. Metoodika valik konk-
reetse uuringu jaoks sõltub ennekõike püstitatud uuringuküsimusest. Üldise 
ravimikasutuse kirjeldamisel võiks eelistada SES metoodikat, mis võimaldab 
väiksema tööjõu ja ressursside kuluga saada ammendavama ülevaate; kogu-
tud andmeid saab kasutada kaudseks individuaalse ekspositsiooni hinda-
miseks üldpopulatsioonis. Kui eesmärgiks on detailne demograafilisi para-
meetreid arvesse võttev ravimikasutuse analüüs, siis tuleks eelistada PPS 
metoodikat, mis võimaldab paremini iseloomustada ravimikasutusega seotud 
individuaalseid riskifaktoreid. 
 
2. Euroopa vastsündinute osakondades on kasutusel üle tuhande erineva ravim-
preparaadi, mille abiainete sisaldus varieerub ulatuslikult. Kolmandik ravim-
preparaatidest sisaldas vähemalt ühte EOI. Suukaudsed ravimvormid 
sisaldasid kõiki uuritud EOI, v.a. bensalkooniumkloriidi, sagedamini kui 
parenteraalselt manustatavad. Eeltoodut tuleks arvesse võtta suukaudsete 
ravimvormide/ ravimpreparaatide määramisel vastsündinutele. 
 
3. Peaaegu kahele kolmandikule vastsündinutest manustati vähemalt ühte 
teadaolevate kõrvaltoimetega abiainet. Gestatsioonivanusega seotud riski 
erinevused tulenesid peamiselt erinevate toimeainete ja ravimpreparaatide 
kasutamisest erinevates gestatsioonigruppides. Äärmiselt enneaegsetele 
manustati võrreldes ajaliste vastsündinutega enam antimikroobseid abiaineid 
106 
(parabeenid, bensoaat). Peamiseks põhjuseks on parenteraalsete antibiooti-
kumide ja suukaudsete multivitamiinide laialdane kasutus selles grupis. 
Võttes arvesse erinevusi toimeainete kasutuses ja manustamisviisides, 
manustati ajalistele vastsündinutele sagedamini lahustite gruppi kuuluvaid 
abiaineid (polüsorbaat80, propüleenglükool) ja magusaineid (sorbitool). 
Nimetatud erinevus võib peegeldada mõningast teadlikku EOI kasutuse 
vältimist äärmiselt enneaegsetel vastsündinutel. Enamikul juhtudel manustati 
just sageli kasutatavate ravimite koostises EOI, seega võiks suhteliselt 
väikese arvu ravimite asendamine EOI-vabade ravimvormidega oluliselt 
vähendada vastsündinute ekspositsiooni nendele ainetele. 
 
4. Kõikide uuritud abiainete klasside kasutuses esines regionaalseid erinevusi. 
Võrreldes ida regiooniga kasutati põhja ja lõuna piirkonnas parabeene 
suurema ning propüleenglükooli ja polüsorbaat 80 väiksema tõenäosusega. 
Magusainete kasutus oli ida regioonis kõikidest teistest piirkondadest mada-
lam. Geograafiliste erinevuste olemasolu näitab, et mitte kõigis tänastes 
ravimites ei ole EOI olemasolu ilmselt hädavajalik. Lisaks viitab see ravim-
preparaatide asendamisvõimalusele Euroopa turul juba olemasolevate ravim-
prepaatidega vältimaks EOI manustamist vastsündinutele. 
 
5. Kaks kolmandikku sagedamini kasutatavatest EOI sisaldavatest ravimprepa-
raatidest oleks teoreetiliselt võimalik asendada EOI-vabade ravimvormidega. 
Selline asendamine Euroopa turul olemasolevate EOI-vabade ravimvormi-
dega säästaks peaaegu pooled vastsündinud ebavajalikust ekspositsioonist. 
Ühtne Euroopa turg ravimite vaba liikumisega aitaks kaasa ravimite asen-
dusvõimaluste kättesaadavuse parandamisele ja stimuleeriks uute ravim-
vormide välja töötamist, kus see osutub vajalikuks. Ravimasenduse võima-
luste rakendamisega seotud tehniliste ja logistiliste küsimuste lahendamiseks 
on vaja kõikide osapoolte tihedat koostööd. 
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